1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Secreted Toxins and Extracellular Enzymes

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • Authors: Kayan Tam1, Victor J. Torres2
  • Editors: Vincent A. Fischetti3, Richard P. Novick4, Joseph J. Ferretti5, Daniel A. Portnoy6, Miriam Braunstein7, Julian I. Rood8
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Department of Microbiology, New York University School of Medicine, Alexandria Center for Life Science, New York, NY 10016; 2: Department of Microbiology, New York University School of Medicine, Alexandria Center for Life Science, New York, NY 10016; 3: The Rockefeller University, New York, NY; 4: Skirball Institute for Molecular Medicine, NYU Medical Center, New York, NY; 5: Department of Microbiology & Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK; 6: Department of Molecular and Cellular Microbiology, University of California, Berkeley, Berkeley, CA; 7: Department of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, NC; 8: Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Australia
  • Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
  • Received 23 July 2018 Accepted 16 August 2018 Published 15 March 2019
  • Victor J. Torres, [email protected]
image of <span class="jp-italic">Staphylococcus aureus</span> Secreted Toxins and Extracellular Enzymes
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Secreted Toxins and Extracellular Enzymes, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/7/2/GPP3-0039-2018-1.gif /docserver/preview/fulltext/microbiolspec/7/2/GPP3-0039-2018-2.gif
  • Abstract:

    is a formidable pathogen capable of causing infections in different sites of the body in a variety of vertebrate animals, including humans and livestock. A major contribution to the success of as a pathogen is the plethora of virulence factors that manipulate the host’s innate and adaptive immune responses. Many of these immune modulating virulence factors are secreted toxins, cofactors for activating host zymogens, and exoenzymes. Secreted toxins such as pore-forming toxins and superantigens are highly inflammatory and can cause leukocyte cell death by cytolysis and clonal deletion, respectively. Coagulases and staphylokinases are cofactors that hijack the host’s coagulation system. Exoenzymes, including nucleases and proteases, cleave and inactivate various immune defense and surveillance molecules, such as complement factors, antimicrobial peptides, and surface receptors that are important for leukocyte chemotaxis. Additionally, some of these secreted toxins and exoenzymes can cause disruption of endothelial and epithelial barriers through cell lysis and cleavage of junction proteins. A unique feature when examining the repertoire of secreted virulence factors is the apparent functional redundancy exhibited by the majority of the toxins and exoenzymes. However, closer examination of each virulence factor revealed that each has unique properties that have important functional consequences. This chapter provides a brief overview of our current understanding of the major secreted virulence factors critical for pathogenesis.

  • Citation: Tam K, Torres V. 2019. Secreted Toxins and Extracellular Enzymes. Microbiol Spectrum 7(2):GPP3-0039-2018. doi:10.1128/microbiolspec.GPP3-0039-2018.

References

1. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28:603–661 http://dx.doi.org/10.1128/CMR.00134-14.
2. Kusch H, Engelmann S. 2014. Secrets of the secretome in Staphylococcus aureus. Int J Med Microbiol 304:133–141 http://dx.doi.org/10.1016/j.ijmm.2013.11.005. [PubMed]
3. Gouaux JE, Braha O, Hobaugh MR, Song L, Cheley S, Shustak C, Bayley H. 1994. Subunit stoichiometry of staphylococcal alpha-hemolysin in crystals and on membranes: a heptameric transmembrane pore. Proc Natl Acad Sci U S A 91:12828–12831 http://dx.doi.org/10.1073/pnas.91.26.12828. [PubMed]
4. Song L, Hobaugh MR, Shustak C, Cheley S, Bayley H, Gouaux JE. 1996. Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 274:1859–1866 http://dx.doi.org/10.1126/science.274.5294.1859. [PubMed]
5. Valeva A, Pongs J, Bhakdi S, Palmer M. 1997. Staphylococcal alpha-toxin: the role of the N-terminus in formation of the heptameric pore—a fluorescence study. Biochim Biophys Acta 1325:281–286 http://dx.doi.org/10.1016/S0005-2736(96)00266-0.
6. Valeva A, Palmer M, Bhakdi S. 1997. Staphylococcal alpha-toxin: formation of the heptameric pore is partially cooperative and proceeds through multiple intermediate stages. Biochemistry 36:13298–13304 http://dx.doi.org/10.1021/bi971075r. [PubMed]
7. Jursch R, Hildebrand A, Hobom G, Tranum-Jensen J, Ward R, Kehoe M, Bhakdi S. 1994. Histidine residues near the N terminus of staphylococcal alpha-toxin as reporters of regions that are critical for oligomerization and pore formation. Infect Immun 62:2249–2256. [PubMed]
8. Menzies BE, Kernodle DS. 1994. Site-directed mutagenesis of the alpha-toxin gene of Staphylococcus aureus: role of histidines in toxin activity in vitro and in a murine model. Infect Immun 62:1843–1847. [PubMed]
9. Cooper LZ, Madoff MA, Weinstein L. 1966. Heat stability and species range of purified staphylococcal alpha-toxin. J Bacteriol 91:1686–1692. [PubMed]
10. Grimminger F, Rose F, Sibelius U, Meinhardt M, Pötzsch B, Spriestersbach R, Bhakdi S, Suttorp N, Seeger W. 1997. Human endothelial cell activation and mediator release in response to the bacterial exotoxins Escherichia coli hemolysin and staphylococcal alpha-toxin. J Immunol 159:1909–1916. [PubMed]
11. Inoshima I, Inoshima N, Wilke GA, Powers ME, Frank KM, Wang Y, Bubeck Wardenburg J. 2011. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med 17:1310–1314 http://dx.doi.org/10.1038/nm.2451. [PubMed]
12. Nygaard TK, Pallister KB, DuMont AL, DeWald M, Watkins RL, Pallister EQ, Malone C, Griffith S, Horswill AR, Torres VJ, Voyich JM. 2012. Alpha-toxin induces programmed cell death of human T cells, B cells, and monocytes during USA300 infection. PLoS One 7:e36532 http://dx.doi.org/10.1371/journal.pone.0036532. [PubMed]
13. Wilke GA, Bubeck Wardenburg J. 2010. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc Natl Acad Sci U S A 107:13473–13478 http://dx.doi.org/10.1073/pnas.1001815107. [PubMed]
14. Popov LM, Marceau CD, Starkl PM, Lumb JH, Shah J, Guerrera D, Cooper RL, Merakou C, Bouley DM, Meng W, Kiyonari H, Takeichi M, Galli SJ, Bagnoli F, Citi S, Carette JE, Amieva MR. 2015. The adherens junctions control susceptibility to Staphylococcus aureus α-toxin. Proc Natl Acad Sci U S A 112:14337–14342 http://dx.doi.org/10.1073/pnas.1510265112. [PubMed]
15. Berube BJ, Bubeck Wardenburg J. 2013. Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel) 5:1140–1166 http://dx.doi.org/10.3390/toxins5061140.
16. Bhakdi S, Muhly M, Korom S, Hugo F. 1989. Release of interleukin-1 beta associated with potent cytocidal action of staphylococcal alpha-toxin on human monocytes. Infect Immun 57:3512–3519. [PubMed]
17. Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, McElvania-Tekippe E, Ting JP, Duncan JA. 2009. Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One 4:e7446 http://dx.doi.org/10.1371/journal.pone.0007446. [PubMed]
18. Suttorp N, Fuhrmann M, Tannert-Otto S, Grimminger F, Bhadki S. 1993. Pore-forming bacterial toxins potently induce release of nitric oxide in porcine endothelial cells. J Exp Med 178:337–341 http://dx.doi.org/10.1084/jem.178.1.337. [PubMed]
19. Suttorp N, Seeger W, Dewein E, Bhakdi S, Roka L. 1985. Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol 248:C127–C134 http://dx.doi.org/10.1152/ajpcell.1985.248.1.C127. [PubMed]
20. Burnet FM. 1929. The exotoxins of Staphylococcus pyogenes aureus. J Pathol Bacteriol 32:717–734 http://dx.doi.org/10.1002/path.1700320402.
21. Gill DM. 1982. Bacterial toxins: a table of lethal amounts. Microbiol Rev 46:86–94. [PubMed]
22. Bayer AS, Ramos MD, Menzies BE, Yeaman MR, Shen AJ, Cheung AL. 1997. Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect Immun 65:4652–4660. [PubMed]
23. Bramley AJ, Patel AH, O’Reilly M, Foster R, Foster TJ. 1989. Roles of alpha-toxin and beta-toxin in virulence of Staphylococcus aureus for the mouse mammary gland. Infect Immun 57:2489–2494. [PubMed]
24. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. 2007. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 13:1405–1406 http://dx.doi.org/10.1038/nm1207-1405. [PubMed]
25. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202:1050–1058 http://dx.doi.org/10.1086/656043. [PubMed]
26. Kielian T, Cheung A, Hickey WF. 2001. Diminished virulence of an alpha-toxin mutant of Staphylococcus aureus in experimental brain abscesses. Infect Immun 69:6902–6911 http://dx.doi.org/10.1128/IAI.69.11.6902-6911.2001. [PubMed]
27. O’Callaghan RJ, Callegan MC, Moreau JM, Green LC, Foster TJ, Hartford OM, Engel LS, Hill JM. 1997. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect Immun 65:1571–1578. [PubMed]
28. Woodin AM. 1960. Purification of the two components of leucocidin from Staphylococcus aureus. Biochem J 75:158–165 http://dx.doi.org/10.1042/bj0750158. [PubMed]
29. Woodin AM. 1959. Fractionation of a leucocidin from Staphylococcus aureus. Biochem J 73:225–237 http://dx.doi.org/10.1042/bj0730225. [PubMed]
30. Alonzo F III, Torres VJ. 2014. The bicomponent pore-forming leucocidins of Staphylococcus aureus. Microbiol Mol Biol Rev 78:199–230 http://dx.doi.org/10.1128/MMBR.00055-13. [PubMed]
31. Seilie ES, Bubeck Wardenburg J. 2017. Staphylococcus aureus pore-forming toxins: the interface of pathogen and host complexity. Semin Cell Dev Biol 72:101–116 http://dx.doi.org/10.1016/j.semcdb.2017.04.003. [PubMed]
32. Spaan AN, van Strijp JAG, Torres VJ. 2017. Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors. Nat Rev Microbiol 15:435–447 http://dx.doi.org/10.1038/nrmicro.2017.27. [PubMed]
33. Yamashita K, Kawai Y, Tanaka Y, Hirano N, Kaneko J, Tomita N, Ohta M, Kamio Y, Yao M, Tanaka I. 2011. Crystal structure of the octameric pore of staphylococcal γ-hemolysin reveals the β-barrel pore formation mechanism by two components. Proc Natl Acad Sci U S A 108:17314–17319 http://dx.doi.org/10.1073/pnas.1110402108. [PubMed]
34. Yamashita D, Sugawara T, Takeshita M, Kaneko J, Kamio Y, Tanaka I, Tanaka Y, Yao M. 2014. Molecular basis of transmembrane beta-barrel formation of staphylococcal pore-forming toxins. Nat Commun 5:4897 http://dx.doi.org/10.1038/ncomms5897. [PubMed]
35. Koop G, Vrieling M, Storisteanu DM, Lok LS, Monie T, van Wigcheren G, Raisen C, Ba X, Gleadall N, Hadjirin N, Timmerman AJ, Wagenaar JA, Klunder HM, Fitzgerald JR, Zadoks R, Paterson GK, Torres C, Waller AS, Loeffler A, Loncaric I, Hoet AE, Bergström K, De Martino L, Pomba C, de Lencastre H, Ben Slama K, Gharsa H, Richardson EJ, Chilvers ER, de Haas C, van Kessel K, van Strijp JA, Harrison EM, Holmes MA. 2017. Identification of LukPQ, a novel, equid-adapted leukocidin of Staphylococcus aureus. Sci Rep 7:40660 http://dx.doi.org/10.1038/srep40660. [PubMed]
36. Vrieling M, Boerhout EM, van Wigcheren GF, Koymans KJ, Mols-Vorstermans TG, de Haas CJ, Aerts PC, Daemen IJ, van Kessel KP, Koets AP, Rutten VP, Nuijten PJ, van Strijp JA, Benedictus L. 2016. LukMF′ is the major secreted leukocidin of bovine Staphylococcus aureus and is produced in vivo during bovine mastitis. Sci Rep 6:37759 http://dx.doi.org/10.1038/srep37759. [PubMed]
37. Yamada T, Tochimaru N, Nakasuji S, Hata E, Kobayashi H, Eguchi M, Kaneko J, Kamio Y, Kaidoh T, Takeuchi S. 2005. Leukotoxin family genes in Staphylococcus aureus isolated from domestic animals and prevalence of lukM-lukF-PV genes by bacteriophages in bovine isolates. Vet Microbiol 110:97–103 http://dx.doi.org/10.1016/j.vetmic.2005.07.006. [PubMed]
38. Yoong P, Torres VJ. 2013. The effects of Staphylococcus aureus leukotoxins on the host: cell lysis and beyond. Curr Opin Microbiol 16:63–69 http://dx.doi.org/10.1016/j.mib.2013.01.012. [PubMed]
39. Badarau A, Rouha H, Malafa S, Logan DT, Håkansson M, Stulik L, Dolezilkova I, Teubenbacher A, Gross K, Maierhofer B, Weber S, Jägerhofer M, Hoffman D, Nagy E. 2015. Structure-function analysis of heterodimer formation, oligomerization, and receptor binding of the Staphylococcus aureus bi-component toxin LukGH. J Biol Chem 290:142–156 http://dx.doi.org/10.1074/jbc.M114.598110. [PubMed]
40. Yanai M, Rocha MA, Matolek AZ, Chintalacharuvu A, Taira Y, Chintalacharuvu K, Beenhouwer DO. 2014. Separately or combined, LukG/LukH is functionally unique compared to other staphylococcal bicomponent leukotoxins. PLoS One 9:e89308 http://dx.doi.org/10.1371/journal.pone.0089308. [PubMed]
41. Noda M, Kato I, Hirayama T, Matsuda F. 1982. Mode of action of staphylococcal leukocidin: effects of the S and F components on the activities of membrane-associated enzymes of rabbit polymorphonuclear leukocytes. Infect Immun 35:38–45. [PubMed]
42. Staali L, Monteil H, Colin DA. 1998. The staphylococcal pore-forming leukotoxins open Ca2+ channels in the membrane of human polymorphonuclear neutrophils. J Membr Biol 162:209–216 http://dx.doi.org/10.1007/s002329900358. [PubMed]
43. Perret M, Badiou C, Lina G, Burbaud S, Benito Y, Bes M, Cottin V, Couzon F, Juruj C, Dauwalder O, Goutagny N, Diep BA, Vandenesch F, Henry T. 2012. Cross-talk between Staphylococcus aureus leukocidins-intoxicated macrophages and lung epithelial cells triggers chemokine secretion in an inflammasome-dependent manner. Cell Microbiol 14:1019–1036 http://dx.doi.org/10.1111/j.1462-5822.2012.01772.x. [PubMed]
44. Spaan AN, Vrieling M, Wallet P, Badiou C, Reyes-Robles T, Ohneck EA, Benito Y, de Haas CJ, Day CJ, Jennings MP, Lina G, Vandenesch F, van Kessel KP, Torres VJ, van Strijp JA, Henry T. 2014. The staphylococcal toxins γ-haemolysin AB and CB differentially target phagocytes by employing specific chemokine receptors. Nat Commun 5:5438 http://dx.doi.org/10.1038/ncomms6438. [PubMed]
45. Holzinger D, Gieldon L, Mysore V, Nippe N, Taxman DJ, Duncan JA, Broglie PM, Marketon K, Austermann J, Vogl T, Foell D, Niemann S, Peters G, Roth J, Löffler B. 2012. Staphylococcus aureus Panton-Valentine leukocidin induces an inflammatory response in human phagocytes via the NLRP3 inflammasome. J Leukoc Biol 92:1069–1081 http://dx.doi.org/10.1189/jlb.0112014. [PubMed]
46. Melehani JH, James DB, DuMont AL, Torres VJ, Duncan JA. 2015. Staphylococcus aureus leukocidin A/B (LukAB) kills human monocytes via host NLRP3 and ASC when extracellular, but not intracellular. PLoS Pathog 11:e1004970 http://dx.doi.org/10.1371/journal.ppat.1004970. [PubMed]
47. Muñoz-Planillo R, Franchi L, Miller LS, Núñez G. 2009. A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J Immunol 183:3942–3948 http://dx.doi.org/10.4049/jimmunol.0900729. [PubMed]
48. Kaneko J, Kimura T, Kawakami Y, Tomita T, Kamio Y. 1997. Panton-Valentine leukocidin genes in a phage-like particle isolated from mitomycin C-treated Staphylococcus aureus V8 (ATCC 49775). Biosci Biotechnol Biochem 61:1960–1962 http://dx.doi.org/10.1271/bbb.61.1960. [PubMed]
49. Kaneko J, Kimura T, Narita S, Tomita T, Kamio Y. 1998. Complete nucleotide sequence and molecular characterization of the temperate staphylococcal bacteriophage phiPVL carrying Panton-Valentine leukocidin genes. Gene 215:57–67 http://dx.doi.org/10.1016/S0378-1119(98)00278-9.
50. McCarthy AJ, Witney AA, Lindsay JA. 2012. Staphylococcus aureus temperate bacteriophage: carriage and horizontal gene transfer is lineage associated. Front Cell Infect Microbiol 2:6 http://dx.doi.org/10.3389/fcimb.2012.00006. [PubMed]
51. Boakes E, Kearns AM, Ganner M, Perry C, Hill RL, Ellington MJ. 2011. Distinct bacteriophages encoding Panton-Valentine leukocidin (PVL) among international methicillin-resistant Staphylococcus aureus clones harboring PVL. J Clin Microbiol 49:684–692 http://dx.doi.org/10.1128/JCM.01917-10. [PubMed]
52. Brown ML, O’Hara FP, Close NM, Mera RM, Miller LA, Suaya JA, Amrine-Madsen H. 2012. Prevalence and sequence variation of Panton-Valentine leukocidin in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the United States. J Clin Microbiol 50:86–90 http://dx.doi.org/10.1128/JCM.05564-11. [PubMed]
53. Boakes E, Kearns AM, Badiou C, Lina G, Hill RL, Ellington MJ. 2012. Do differences in Panton-Valentine leukocidin production among international methicillin-resistant Staphylococcus aureus clones affect disease presentation and severity? J Clin Microbiol 50:1773–1776 http://dx.doi.org/10.1128/JCM.06421-11. [PubMed]
54. Hamilton SM, Bryant AE, Carroll KC, Lockary V, Ma Y, McIndoo E, Miller LG, Perdreau-Remington F, Pullman J, Risi GF, Salmi DB, Stevens DL. 2007. In vitro production of Panton-Valentine leukocidin among strains of methicillin-resistant Staphylococcus aureus causing diverse infections. Clin Infect Dis 45:1550–1558 http://dx.doi.org/10.1086/523581. [PubMed]
55. Tromp AT, Van Gent M, Abrial P, Martin A, Jansen JP, De Haas CJC, Van Kessel KPM, Bardoel BW, Kruse E, Bourdonnay E, Boettcher M, McManus MT, Day CJ, Jennings MP, Lina G, Vandenesch F, Van Strijp JAG, Jan Lebbink R, Haas PA, Henry T, Spaan AN. 2018. Human CD45 is an F-component-specific receptor for the staphylococcal toxin Panton-Valentine leukocidin. Nat Microbiol 3:708–717. [PubMed]
56. Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, Marbach H, Mai TT, Sarda MN, Kajikawa O, Matute-Bello G, Tkaczyk C, Rasigade JP, Sellman BR, Chambers HF, Lina G. 2016. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med 8:357ra124 http://dx.doi.org/10.1126/scitranslmed.aag1153.
57. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. 2010. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A 107:5587–5592 http://dx.doi.org/10.1073/pnas.0912403107. [PubMed]
58. Spaan AN, Henry T, van Rooijen WJM, Perret M, Badiou C, Aerts PC, Kemmink J, de Haas CJC, van Kessel KPM, Vandenesch F, Lina G, van Strijp JAG. 2013. The staphylococcal toxin Panton-Valentine leukocidin targets human C5a receptors. Cell Host Microbe 13:584–594 http://dx.doi.org/10.1016/j.chom.2013.04.006. [PubMed]
59. Spaan AN, Schiepers A, de Haas CJ, van Hooijdonk DD, Badiou C, Contamin H, Vandenesch F, Lina G, Gerard NP, Gerard C, van Kessel KP, Henry T, van Strijp JA. 2015. Differential Interaction of the staphylococcal toxins Panton-Valentine leukocidin and γ-hemolysin CB with human C5a receptors. J Immunol 195:1034–1043 http://dx.doi.org/10.4049/jimmunol.1500604. [PubMed]
60. Crémieux AC, Dumitrescu O, Lina G, Vallee C, Côté JF, Muffat-Joly M, Lilin T, Etienne J, Vandenesch F, Saleh-Mghir A. 2009. Panton-Valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One 4:e7204 http://dx.doi.org/10.1371/journal.pone.0007204. [PubMed]
61. Graves SF, Kobayashi SD, Braughton KR, Whitney AR, Sturdevant DE, Rasmussen DL, Kirpotina LN, Quinn MT, DeLeo FR. 2012. Sublytic concentrations of Staphylococcus aureus Panton-Valentine leukocidin alter human PMN gene expression and enhance bactericidal capacity. J Leukoc Biol 92:361–374 http://dx.doi.org/10.1189/jlb.1111575. [PubMed]
62. Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, Long D, Bubeck Wardenburg J, Schneewind O, Otto M, Deleo FR. 2011. Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis 204:937–941 http://dx.doi.org/10.1093/infdis/jir441. [PubMed]
63. Chi CY, Lin CC, Liao IC, Yao YC, Shen FC, Liu CC, Lin CF. 2014. Panton-Valentine leukocidin facilitates the escape of Staphylococcus aureus from human keratinocyte endosomes and induces apoptosis. J Infect Dis 209:224–235 http://dx.doi.org/10.1093/infdis/jit445. [PubMed]
64. McCarthy AJ, Lindsay JA. 2013. Staphylococcus aureus innate immune evasion is lineage-specific: a bioinfomatics study. Infect Genet Evol 19:7–14 http://dx.doi.org/10.1016/j.meegid.2013.06.012. [PubMed]
65. von Eiff C, Friedrich AW, Peters G, Becker K. 2004. Prevalence of genes encoding for members of the staphylococcal leukotoxin family among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis 49:157–162 http://dx.doi.org/10.1016/j.diagmicrobio.2004.03.009. [PubMed]
66. Cooney J, Kienle Z, Foster TJ, O’Toole PW. 1993. The gamma-hemolysin locus of Staphylococcus aureus comprises three linked genes, two of which are identical to the genes for the F and S components of leukocidin. Infect Immun 61:768–771. [PubMed]
67. Spaan AN, Reyes-Robles T, Badiou C, Cochet S, Boguslawski KM, Yoong P, Day CJ, de Haas CJ, van Kessel KP, Vandenesch F, Jennings MP, Le Van Kim C, Colin Y, van Strijp JA, Henry T, Torres VJ. 2015. Staphylococcus aureus targets the Duffy antigen receptor for chemokines (DARC) to lyse erythrocytes. Cell Host Microbe 18:363–370 http://dx.doi.org/10.1016/j.chom.2015.08.001. [PubMed]
68. Reyes-Robles T, Lubkin A, Alonzo F III, Lacy DB, Torres VJ. 2016. Exploiting dominant-negative toxins to combat Staphylococcus aureus pathogenesis. EMBO Rep 17:428–440 http://dx.doi.org/10.15252/embr.201540994. [PubMed]
69. Siqueira JA, Speeg-Schatz C, Freitas FI, Sahel J, Monteil H, Prévost G. 1997. Channel-forming leucotoxins from Staphylococcus aureus cause severe inflammatory reactions in a rabbit eye model. J Med Microbiol 46:486–494 http://dx.doi.org/10.1099/00222615-46-6-486. [PubMed]
70. Nilsson IM, Hartford O, Foster T, Tarkowski A. 1999. Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis. Infect Immun 67:1045–1049. [PubMed]
71. Supersac G, Piémont Y, Kubina M, Prévost G, Foster TJ. 1998. Assessment of the role of gamma-toxin in experimental endophthalmitis using a hlg-deficient mutant of Staphylococcus aureus. Microb Pathog 24:241–251 http://dx.doi.org/10.1006/mpat.1997.0192. [PubMed]
72. Malachowa N, Whitney AR, Kobayashi SD, Sturdevant DE, Kennedy AD, Braughton KR, Shabb DW, Diep BA, Chambers HF, Otto M, DeLeo FR. 2011. Global changes in Staphylococcus aureus gene expression in human blood. PLoS One 6:e18617 http://dx.doi.org/10.1371/journal.pone.0018617. [PubMed]
73. Gravet A, Colin DA, Keller D, Girardot R, Monteil H, Prévost G. 1998. Characterization of a novel structural member, LukE-LukD, of the bi-component staphylococcal leucotoxins family. FEBS Lett 436:202–208 http://dx.doi.org/10.1016/S0014-5793(98)01130-2.
74. Morinaga N, Kaihou Y, Noda M. 2003. Purification, cloning and characterization of variant LukE-LukD with strong leukocidal activity of staphylococcal bi-component leukotoxin family. Microbiol Immunol 47:81–90 http://dx.doi.org/10.1111/j.1348-0421.2003.tb02789.x. [PubMed]
75. Alonzo F III, Benson MA, Chen J, Novick RP, Shopsin B, Torres VJ. 2012. Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. Mol Microbiol 83:423–435 http://dx.doi.org/10.1111/j.1365-2958.2011.07942.x. [PubMed]
76. Alonzo F III, Kozhaya L, Rawlings SA, Reyes-Robles T, DuMont AL, Myszka DG, Landau NR, Unutmaz D, Torres VJ. 2013. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 493:51–55 http://dx.doi.org/10.1038/nature11724. [PubMed]
77. Reyes-Robles T, Alonzo F III, Kozhaya L, Lacy DB, Unutmaz D, Torres VJ. 2013. Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infection. Cell Host Microbe 14:453–459 http://dx.doi.org/10.1016/j.chom.2013.09.005. [PubMed]
78. Dumont AL, Nygaard TK, Watkins RL, Smith A, Kozhaya L, Kreiswirth BN, Shopsin B, Unutmaz D, Voyich JM, Torres VJ. 2011. Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol Microbiol 79:814–825 http://dx.doi.org/10.1111/j.1365-2958.2010.07490.x. [PubMed]
79. Ventura CL, Malachowa N, Hammer CH, Nardone GA, Robinson MA, Kobayashi SD, DeLeo FR. 2010. Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS One 5:e11634 http://dx.doi.org/10.1371/journal.pone.0011634. [PubMed]
80. DuMont AL, Yoong P, Liu X, Day CJ, Chumbler NM, James DB, Alonzo F III, Bode NJ, Lacy DB, Jennings MP, Torres VJ. 2014. Identification of a crucial residue required for Staphylococcus aureus LukAB cytotoxicity and receptor recognition. Infect Immun 82:1268–1276 http://dx.doi.org/10.1128/IAI.01444-13. [PubMed]
81. Malachowa N, Kobayashi SD, Braughton KR, Whitney AR, Parnell MJ, Gardner DJ, Deleo FR. 2012. Staphylococcus aureus leukotoxin GH promotes inflammation. J Infect Dis 206:1185–1193 http://dx.doi.org/10.1093/infdis/jis495. [PubMed]
82. DuMont AL, Yoong P, Day CJ, Alonzo F III, McDonald WH, Jennings MP, Torres VJ. 2013. Staphylococcus aureus LukAB cytotoxin kills human neutrophils by targeting the CD11b subunit of the integrin Mac-1. Proc Natl Acad Sci U S A 110:10794–10799 http://dx.doi.org/10.1073/pnas.1305121110. [PubMed]
83. DuMont AL, Yoong P, Surewaard BG, Benson MA, Nijland R, van Strijp JA, Torres VJ. 2013. Staphylococcus aureus elaborates leukocidin AB to mediate escape from within human neutrophils. Infect Immun 81:1830–1841 http://dx.doi.org/10.1128/IAI.00095-13. [PubMed]
84. Thomsen IP, Dumont AL, James DB, Yoong P, Saville BR, Soper N, Torres VJ, Creech CB. 2014. Children with invasive Staphylococcus aureus disease exhibit a potently neutralizing antibody response to the cytotoxin LukAB. Infect Immun 82:1234–1242 http://dx.doi.org/10.1128/IAI.01558-13. [PubMed]
85. Chadha AD, Thomsen IP, Jimenez-Truque N, Soper NR, Jones LS, Sokolow AG, Torres VJ, Creech CB. 2016. Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis. J Cyst Fibros 15:597–604 http://dx.doi.org/10.1016/j.jcf.2015.12.023. [PubMed]
86. Rainard P, Corrales JC, Barrio MB, Cochard T, Poutrel B. 2003. Leucotoxic activities of Staphylococcus aureus strains isolated from cows, ewes, and goats with mastitis: importance of LukM/LukF′-PV leukotoxin. Clin Diagn Lab Immunol 10:272–277.
87. Vrieling M, Koymans KJ, Heesterbeek DA, Aerts PC, Rutten VP, de Haas CJ, van Kessel KP, Koets AP, Nijland R, van Strijp JA. 2015. Bovine Staphylococcus aureus secretes the leukocidin LukMF′ to kill migrating neutrophils through CCR1. MBio 6:e00335 http://dx.doi.org/10.1128/mBio.00335-15. [PubMed]
88. Fromageau A, Cunha P, Gilbert FB, Rainard P. 2011. Purified Staphylococcus aureus leukotoxin LukM/F′ does not trigger inflammation in the bovine mammary gland. Microb Pathog 51:396–401 http://dx.doi.org/10.1016/j.micpath.2011.09.005. [PubMed]
89. Janzon L, Arvidson S. 1990. The role of the delta-lysin gene ( hld) in the regulation of virulence genes by the accessory gene regulator ( agr) in Staphylococcus aureus. EMBO J 9:1391–1399 http://dx.doi.org/10.1002/j.1460-2075.1990.tb08254.x. [PubMed]
90. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, DeLeo FR, Otto M. 2007. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13:1510–1514 http://dx.doi.org/10.1038/nm1656. [PubMed]
91. Queck SY, Khan BA, Wang R, Bach TH, Kretschmer D, Chen L, Kreiswirth BN, Peschel A, Deleo FR, Otto M. 2009. Mobile genetic element-encoded cytolysin connects virulence to methicillin resistance in MRSA. PLoS Pathog 5:e1000533 http://dx.doi.org/10.1371/journal.ppat.1000533. [PubMed]
92. Kaito C, Saito Y, Nagano G, Ikuo M, Omae Y, Hanada Y, Han X, Kuwahara-Arai K, Hishinuma T, Baba T, Ito T, Hiramatsu K, Sekimizu K. 2011. Transcription and translation products of the cytolysin gene psm-mec on the mobile genetic element SCC mec regulate Staphylococcus aureus virulence. PLoS Pathog 7:e1001267 http://dx.doi.org/10.1371/journal.ppat.1001267. [PubMed]
93. Somerville GA, Cockayne A, Dürr M, Peschel A, Otto M, Musser JM. 2003. Synthesis and deformylation of Staphylococcus aureus delta-toxin are linked to tricarboxylic acid cycle activity. J Bacteriol 185:6686–6694 http://dx.doi.org/10.1128/JB.185.22.6686-6694.2003. [PubMed]
94. Chatterjee SS, Joo HS, Duong AC, Dieringer TD, Tan VY, Song Y, Fischer ER, Cheung GY, Li M, Otto M. 2013. Essential Staphylococcus aureus toxin export system. Nat Med 19:364–367 http://dx.doi.org/10.1038/nm.3047. [PubMed]
95. Peschel A, Otto M. 2013. Phenol-soluble modulins and staphylococcal infection. Nat Rev Microbiol 11:667–673 http://dx.doi.org/10.1038/nrmicro3110. [PubMed]
96. Tappin MJ, Pastore A, Norton RS, Freer JH, Campbell ID. 1988. High-resolution 1H NMR study of the solution structure of delta-hemolysin. Biochemistry 27:1643–1647 http://dx.doi.org/10.1021/bi00405a038. [PubMed]
97. Towle KM, Lohans CT, Miskolzie M, Acedo JZ, van Belkum MJ, Vederas JC. 2016. Solution structures of phenol-soluble modulins α1, α3, and β2, virulence factors from Staphylococcus aureus. Biochemistry 55:4798–4806 http://dx.doi.org/10.1021/acs.biochem.6b00615. [PubMed]
98. Cheung GY, Duong AC, Otto M. 2012. Direct and synergistic hemolysis caused by Staphylococcus phenol-soluble modulins: implications for diagnosis and pathogenesis. Microbes Infect 14:380–386 http://dx.doi.org/10.1016/j.micinf.2011.11.013. [PubMed]
99. Rasigade JP, Trouillet-Assant S, Ferry T, Diep BA, Sapin A, Lhoste Y, Ranfaing J, Badiou C, Benito Y, Bes M, Couzon F, Tigaud S, Lina G, Etienne J, Vandenesch F, Laurent F. 2013. PSMs of hypervirulent Staphylococcus aureus act as intracellular toxins that kill infected osteoblasts. PLoS One 8:e63176 http://dx.doi.org/10.1371/journal.pone.0063176. [PubMed]
100. Surewaard BG, de Haas CJ, Vervoort F, Rigby KM, DeLeo FR, Otto M, van Strijp JA, Nijland R. 2013. Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis. Cell Microbiol 15:1427–1437 http://dx.doi.org/10.1111/cmi.12130. [PubMed]
101. Surewaard BG, Nijland R, Spaan AN, Kruijtzer JA, de Haas CJ, van Strijp JA. 2012. Inactivation of staphylococcal phenol soluble modulins by serum lipoprotein particles. PLoS Pathog 8:e1002606 http://dx.doi.org/10.1371/journal.ppat.1002606. [PubMed]
102. Kretschmer D, Gleske AK, Rautenberg M, Wang R, Köberle M, Bohn E, Schöneberg T, Rabiet MJ, Boulay F, Klebanoff SJ, van Kessel KA, van Strijp JA, Otto M, Peschel A. 2010. Human formyl peptide receptor 2 senses highly pathogenic Staphylococcus aureus. Cell Host Microbe 7:463–473 http://dx.doi.org/10.1016/j.chom.2010.05.012. [PubMed]
103. Periasamy S, Joo HS, Duong AC, Bach TH, Tan VY, Chatterjee SS, Cheung GY, Otto M. 2012. How Staphylococcus aureus biofilms develop their characteristic structure. Proc Natl Acad Sci U S A 109:1281–1286 http://dx.doi.org/10.1073/pnas.1115006109. [PubMed]
104. Ebner P, Luqman A, Reichert S, Hauf K, Popella P, Forchhammer K, Otto M, Götz F. 2017. Non-classical protein excretion is boosted by PSMα-induced cell leakage. Cell Reports 20:1278–1286 http://dx.doi.org/10.1016/j.celrep.2017.07.045. [PubMed]
105. Merriman JA, Klingelhutz AJ, Diekema DJ, Leung DY, Schlievert PM. 2015. Novel Staphylococcus aureus secreted protein alters keratinocyte proliferation and elicits a proinflammatory response in vitro and in vivo. Biochemistry 54:4855–4862 http://dx.doi.org/10.1021/acs.biochem.5b00523. [PubMed]
106. Spaulding AR, Salgado-Pabón W, Kohler PL, Horswill AR, Leung DY, Schlievert PM. 2013. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev 26:422–447 http://dx.doi.org/10.1128/CMR.00104-12. [PubMed]
107. Wilson GJ, Seo KS, Cartwright RA, Connelley T, Chuang-Smith ON, Merriman JA, Guinane CM, Park JY, Bohach GA, Schlievert PM, Morrison WI, Fitzgerald JR. 2011. A novel core genome-encoded superantigen contributes to lethality of community-associated MRSA necrotizing pneumonia. PLoS Pathog 7:e1002271 http://dx.doi.org/10.1371/journal.ppat.1002271. [PubMed]
108. Ono HK, Omoe K, Imanishi K, Iwakabe Y, Hu DL, Kato H, Saito N, Nakane A, Uchiyama T, Shinagawa K. 2008. Identification and characterization of two novel staphylococcal enterotoxins, types S and T. Infect Immun 76:4999–5005 http://dx.doi.org/10.1128/IAI.00045-08. [PubMed]
109. Fitzgerald JR, Monday SR, Foster TJ, Bohach GA, Hartigan PJ, Meaney WJ, Smyth CJ. 2001. Characterization of a putative pathogenicity island from bovine Staphylococcus aureus encoding multiple superantigens. J Bacteriol 183:63–70 http://dx.doi.org/10.1128/JB.183.1.63-70.2001. [PubMed]
110. Johns MB Jr, Khan SA. 1988. Staphylococcal enterotoxin B gene is associated with a discrete genetic element. J Bacteriol 170:4033–4039 http://dx.doi.org/10.1128/jb.170.9.4033-4039.1988. [PubMed]
111. Langley R, Patel D, Jackson N, Clow F, Fraser JD. 2010. Staphylococcal superantigen super-domains in immune evasion. Crit Rev Immunol 30:149–165 http://dx.doi.org/10.1615/CritRevImmunol.v30.i2.40. [PubMed]
112. Lindsay JA, Holden MT. 2006. Understanding the rise of the superbug: investigation of the evolution and genomic variation of Staphylococcus aureus. Funct Integr Genomics 6:186–201 http://dx.doi.org/10.1007/s10142-005-0019-7. [PubMed]
113. Fitzgerald JR, Reid SD, Ruotsalainen E, Tripp TJ, Liu M, Cole R, Kuusela P, Schlievert PM, Järvinen A, Musser JM. 2003. Genome diversification in Staphylococcus aureus: molecular evolution of a highly variable chromosomal region encoding the staphylococcal exotoxin-like family of proteins. Infect Immun 71:2827–2838 http://dx.doi.org/10.1128/IAI.71.5.2827-2838.2003. [PubMed]
114. Lina G, Bohach GA, Nair SP, Hiramatsu K, Jouvin-Marche E, Mariuzza R, International Nomenclature Committee for Staphylococcal Superantigens. 2004. Standard nomenclature for the superantigens expressed by Staphylococcus. J Infect Dis 189:2334–2336 http://dx.doi.org/10.1086/420852. [PubMed]
115. Mitchell DT, Levitt DG, Schlievert PM, Ohlendorf DH. 2000. Structural evidence for the evolution of pyrogenic toxin superantigens. J Mol Evol 51:520–531 http://dx.doi.org/10.1007/s002390010116. [PubMed]
116. Rödström KE, Elbing K, Lindkvist-Petersson K. 2014. Structure of the superantigen staphylococcal enterotoxin B in complex with TCR and peptide-MHC demonstrates absence of TCR-peptide contacts. J Immunol 193:1998–2004 http://dx.doi.org/10.4049/jimmunol.1401268. [PubMed]
117. Kozono H, Parker D, White J, Marrack P, Kappler J. 1995. Multiple binding sites for bacterial superantigens on soluble class II MHC molecules. Immunity 3:187–196 http://dx.doi.org/10.1016/1074-7613(95)90088-8.
118. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Chi YI, Stauffacher C, Strominger JL, Wiley DC. 1994. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 368:711–718 http://dx.doi.org/10.1038/368711a0. [PubMed]
119. Petersson K, Thunnissen M, Forsberg G, Walse B. 2002. Crystal structure of a SEA variant in complex with MHC class II reveals the ability of SEA to crosslink MHC molecules. Structure 10:1619–1626 http://dx.doi.org/10.1016/S0969-2126(02)00895-X.
120. Günther S, Varma AK, Moza B, Kasper KJ, Wyatt AW, Zhu P, Rahman AK, Li Y, Mariuzza RA, McCormick JK, Sundberg EJ. 2007. A novel loop domain in superantigens extends their T cell receptor recognition site. J Mol Biol 371:210–221 http://dx.doi.org/10.1016/j.jmb.2007.05.038. [PubMed]
121. Novick RP. 2003. Mobile genetic elements and bacterial toxinoses: the superantigen-encoding pathogenicity islands of Staphylococcus aureus. Plasmid 49:93–105 http://dx.doi.org/10.1016/S0147-619X(02)00157-9.
122. Kim J, Urban RG, Strominger JL, Wiley DC. 1994. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 266:1870–1874 http://dx.doi.org/10.1126/science.7997880. [PubMed]
123. Brosnahan AJ, Schaefers MM, Amundson WH, Mantz MJ, Squier CA, Peterson ML, Schlievert PM. 2008. Novel toxic shock syndrome toxin-1 amino acids required for biological activity. Biochemistry 47:12995–13003 http://dx.doi.org/10.1021/bi801468w. [PubMed]
124. Arad G, Levy R, Nasie I, Hillman D, Rotfogel Z, Barash U, Supper E, Shpilka T, Minis A, Kaempfer R. 2011. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol 9:e1001149 http://dx.doi.org/10.1371/journal.pbio.1001149. [PubMed]
125. Spaulding AR, Lin YC, Merriman JA, Brosnahan AJ, Peterson ML, Schlievert PM. 2012. Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses. Vaccine 30:5099–5109 http://dx.doi.org/10.1016/j.vaccine.2012.05.067. [PubMed]
126. CDC. 2011. Toxic shock syndrome (other than streptococcal) TSS: 2011 case definition. https://wwwn.cdc.gov/nndss/conditions/toxic-shock-syndrome-other-than-streptococcal/case-definition/2011/.
127. Davis JP, Chesney PJ, Wand PJ, LaVenture M. 1980. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 303:1429–1435 http://dx.doi.org/10.1056/NEJM198012183032501.
128. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, Anderson RL, Hill DL, Broome CV, Band JD, Fraser DW. 1980. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 303:1436–1442 http://dx.doi.org/10.1056/NEJM198012183032502. [PubMed]
129. Schlievert PM. 1986. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet 1:1149–1150 http://dx.doi.org/10.1016/S0140-6736(86)91859-3.
130. Shopsin B, Gomez M, Montgomery SO, Smith DH, Waddington M, Dodge DE, Bost DA, Riehman M, Naidich S, Kreiswirth BN. 1999. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol 37:3556–3563. [PubMed]
131. Kim HK, Thammavongsa V, Schneewind O, Missiakas D. 2012. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 15:92–99 http://dx.doi.org/10.1016/j.mib.2011.10.012. [PubMed]
132. Guss B, Uhlén M, Nilsson B, Lindberg M, Sjöquist J, Sjödahl J. 1984. Region X, the cell-wall-attachment part of staphylococcal protein A. Eur J Biochem 138:413–420 http://dx.doi.org/10.1111/j.1432-1033.1984.tb07931.x. [PubMed]
133. Becker S, Frankel MB, Schneewind O, Missiakas D. 2014. Release of protein A from the cell wall of Staphylococcus aureus. Proc Natl Acad Sci U S A 111:1574–1579 http://dx.doi.org/10.1073/pnas.1317181111. [PubMed]
134. Peterson PK, Verhoef J, Sabath LD, Quie PG. 1977. Effect of protein A on staphylococcal opsonization. Infect Immun 15:760–764. [PubMed]
135. Sasso EH, Silverman GJ, Mannik M. 1989. Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. J Immunol 142:2778–2783. [PubMed]
136. Romagnani S, Giudizi MG, del Prete G, Maggi E, Biagiotti R, Almerigogna F, Ricci M. 1982. Demonstration on protein A of two distinct immunoglobulin-binding sites and their role in the mitogenic activity of Staphylococcus aureus Cowan I on human B cells. J Immunol 129:596–602. [PubMed]
137. Goodyear CS, Silverman GJ. 2003. Death by a B cell superantigen: in vivo VH-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin. J Exp Med 197:1125–1139 http://dx.doi.org/10.1084/jem.20020552. [PubMed]
138. Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, Charbonnier JB, Silverman GJ. 2000. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci U S A 97:5399–5404 http://dx.doi.org/10.1073/pnas.97.10.5399. [PubMed]
139. Silverman GJ, Goodyear CS. 2006. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 6:465–475 http://dx.doi.org/10.1038/nri1853. [PubMed]
140. Pauli NT, Kim HK, Falugi F, Huang M, Dulac J, Henry Dunand C, Zheng NY, Kaur K, Andrews SF, Huang Y, DeDent A, Frank KM, Charnot-Katsikas A, Schneewind O, Wilson PC. 2014. Staphylococcus aureus infection induces protein A-mediated immune evasion in humans. J Exp Med 211:2331–2339 http://dx.doi.org/10.1084/jem.20141404. [PubMed]
141. Keener AB, Thurlow LT, Kang S, Spidale NA, Clarke SH, Cunnion KM, Tisch R, Richardson AR, Vilen BJ. 2017. Staphylococcus aureus protein A disrupts immunity mediated by long-lived plasma cells. J Immunol 198:1263–1273 http://dx.doi.org/10.4049/jimmunol.1600093. [PubMed]
142. Falugi F, Kim HK, Missiakas DM, Schneewind O. 2013. Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus. MBio 4:e00575-13 http://dx.doi.org/10.1128/mBio.00575-13. [PubMed]
143. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. 2010. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 207:1863–1870 http://dx.doi.org/10.1084/jem.20092514. [PubMed]
144. Winkler KC, de Waart J, Grootsen C, Zegers BJM, Tellier NF, Vertregt CD. 1965. Lysogenic conversion of staphylococci to loss of beta-toxin. J Gen Microbiol 39:321–333 http://dx.doi.org/10.1099/00221287-39-3-321. [PubMed]
145. Verkaik NJ, Benard M, Boelens HA, de Vogel CP, Nouwen JL, Verbrugh HA, Melles DC, van Belkum A, van Wamel WJ. 2011. Immune evasion cluster-positive bacteriophages are highly prevalent among human Staphylococcus aureus strains, but they are not essential in the first stages of nasal colonization. Clin Microbiol Infect 17:343–348 http://dx.doi.org/10.1111/j.1469-0691.2010.03227.x. [PubMed]
146. Aarestrup FM, Larsen HD, Eriksen NH, Elsberg CS, Jensen NE. 1999. Frequency of alpha- and beta-haemolysin in Staphylococcus aureus of bovine and human origin. A comparison between pheno- and genotype and variation in phenotypic expression. APMIS 107:425–430 http://dx.doi.org/10.1111/j.1699-0463.1999.tb01576.x. [PubMed]
147. Salgado-Pabón W, Herrera A, Vu BG, Stach CS, Merriman JA, Spaulding AR, Schlievert PM. 2014. Staphylococcus aureus β-toxin production is common in strains with the β-toxin gene inactivated by bacteriophage. J Infect Dis 210:784–792 http://dx.doi.org/10.1093/infdis/jiu146. [PubMed]
148. Goerke C, Matias y Papenberg S, Dasbach S, Dietz K, Ziebach R, Kahl BC, Wolz C. 2004. Increased frequency of genomic alterations in Staphylococcus aureus during chronic infection is in part due to phage mobilization. J Infect Dis 189:724–734 http://dx.doi.org/10.1086/381502. [PubMed]
149. Goerke C, Köller J, Wolz C. 2006. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob Agents Chemother 50:171–177 http://dx.doi.org/10.1128/AAC.50.1.171-177.2006. [PubMed]
150. Goerke C, Wirtz C, Flückiger U, Wolz C. 2006. Extensive phage dynamics in Staphylococcus aureus contributes to adaptation to the human host during infection. Mol Microbiol 61:1673–1685 http://dx.doi.org/10.1111/j.1365-2958.2006.05354.x. [PubMed]
151. Doery HM, Magnusson BJ, Cheyne IM, Sulasekharam J. 1963. A phospholipase in staphylococcal toxin which hydrolyses sphingomyelin. Nature 198:1091–1092 http://dx.doi.org/10.1038/1981091a0. [PubMed]
152. Glenny AT, Stevens MF. 1935. Staphylococcus toxins and antitoxins. J Pathol Bacteriol 40:201–210 http://dx.doi.org/10.1002/path.1700400202.
153. Low DK, Freer JH, Arbuthnott JP, Möllby R, Wadström T. 1974. Consequences of spingomyelin degradation in erythrocyte ghost membranes by staphylococcal beta-toxin (sphingomyelinase C). Toxicon 12:279–285 http://dx.doi.org/10.1016/0041-0101(74)90070-1.
154. Huseby M, Shi K, Brown CK, Digre J, Mengistu F, Seo KS, Bohach GA, Schlievert PM, Ohlendorf DH, Earhart CA. 2007. Structure and biological activities of beta toxin from Staphylococcus aureus. J Bacteriol 189:8719–8726 http://dx.doi.org/10.1128/JB.00741-07. [PubMed]
155. Huseby MJ, Kruse AC, Digre J, Kohler PL, Vocke JA, Mann EE, Bayles KW, Bohach GA, Schlievert PM, Ohlendorf DH, Earhart CA. 2010. Beta toxin catalyzes formation of nucleoprotein matrix in staphylococcal biofilms. Proc Natl Acad Sci U S A 107:14407–14412 http://dx.doi.org/10.1073/pnas.0911032107. [PubMed]
156. Bernheimer AW, Avigad LS, Kim KS. 1974. Staphylococcal sphingomyelinase (beta-hemolysin). Ann N Y Acad Sci 236:292–306 http://dx.doi.org/10.1111/j.1749-6632.1974.tb41499.x. [PubMed]
157. Cifrian E, Guidry AJ, Bramley AJ, Norcross NL, Bastida-Corcuera FD, Marquardt WW. 1996. Effect of staphylococcal beta toxin on the cytotoxicity, proliferation and adherence of Staphylococcus aureus to bovine mammary epithelial cells. Vet Microbiol 48:187–198 http://dx.doi.org/10.1016/0378-1135(95)00159-X.
158. Walev I, Weller U, Strauch S, Foster T, Bhakdi S. 1996. Selective killing of human monocytes and cytokine release provoked by sphingomyelinase (beta-toxin) of Staphylococcus aureus. Infect Immun 64:2974–2979. [PubMed]
159. Katayama Y, Baba T, Sekine M, Fukuda M, Hiramatsu K. 2013. Beta-hemolysin promotes skin colonization by Staphylococcus aureus. J Bacteriol 195:1194–1203 http://dx.doi.org/10.1128/JB.01786-12. [PubMed]
160. Tajima A, Iwase T, Shinji H, Seki K, Mizunoe Y. 2009. Inhibition of endothelial interleukin-8 production and neutrophil transmigration by Staphylococcus aureus beta-hemolysin. Infect Immun 77:327–334 http://dx.doi.org/10.1128/IAI.00748-08. [PubMed]
161. Herrera A, Vu BG, Stach CS, Merriman JA, Horswill AR, Salgado-Pabón W, Schlievert PM. 2016. Staphylococcus aureus β-toxin mutants are defective in biofilm ligase and sphingomyelinase activity, and causation of infective endocarditis and sepsis. Biochemistry 55:2510–2517 http://dx.doi.org/10.1021/acs.biochem.6b00083. [PubMed]
162. Hayashida A, Bartlett AH, Foster TJ, Park PW. 2009. Staphylococcus aureus beta-toxin induces lung injury through syndecan-1. Am J Pathol 174:509–518 http://dx.doi.org/10.2353/ajpath.2009.080394. [PubMed]
163. Kondo I, Sakurai S, Sarai Y. 1973. Purification of exfoliatin produced by Staphylococcus aureus of bacteriophage group 2 and its physicochemical properties. Infect Immun 8:156–164. [PubMed]
164. Yamaguchi T, Hayashi T, Takami H, Nakasone K, Ohnishi M, Nakayama K, Yamada S, Komatsuzawa H, Sugai M. 2000. Phage conversion of exfoliative toxin A production in Staphylococcus aureus. Mol Microbiol 38:694–705 http://dx.doi.org/10.1046/j.1365-2958.2000.02169.x. [PubMed]
165. O’Reilly M, Dougan G, Foster TJ, Arbuthnott JP. 1981. Plasmids in epidermolytic strains of Staphylococcus aureus. J Gen Microbiol 124:99–107.
166. Yamaguchi T, Nishifuji K, Sasaki M, Fudaba Y, Aepfelbacher M, Takata T, Ohara M, Komatsuzawa H, Amagai M, Sugai M. 2002. Identification of the Staphylococcus aureusetd pathogenicity island which encodes a novel exfoliative toxin, ETD, and EDIN-B. Infect Immun 70:5835–5845 http://dx.doi.org/10.1128/IAI.70.10.5835-5845.2002. [PubMed]
167. Sato H, Matsumori Y, Tanabe T, Saito H, Shimizu A, Kawano J. 1994. A new type of staphylococcal exfoliative toxin from a Staphylococcus aureus strain isolated from a horse with phlegmon. Infect Immun 62:3780–3785. [PubMed]
168. Bukowski M, Wladyka B, Dubin G. 2010. Exfoliative toxins of Staphylococcus aureus. Toxins (Basel) 2:1148–1165 http://dx.doi.org/10.3390/toxins2051148. [PubMed]
169. Lyell A. 1967. A review of toxic epidermal necrolysis in Britain. Br J Dermatol 79:662–671 http://dx.doi.org/10.1111/j.1365-2133.1967.tb11434.x. [PubMed]
170. Lyell A. 1983. The staphylococcal scalded skin syndrome in historical perspective: emergence of dermopathic strains of Staphylococcus aureus and discovery of the epidermolytic toxin. A review of events up to 1970. J Am Acad Dermatol 9:285–294 http://dx.doi.org/10.1016/S0190-9622(83)80161-3.
171. Melish ME, Glasgow LA. 1970. The staphylococcal scalded-skin syndrome. N Engl J Med 282:1114–1119 http://dx.doi.org/10.1056/NEJM197005142822002. [PubMed]
172. Cavarelli J, Prévost G, Bourguet W, Moulinier L, Chevrier B, Delagoutte B, Bilwes A, Mourey L, Rifai S, Piémont Y, Moras D. 1997. The structure of Staphylococcus aureus epidermolytic toxin A, an atypic serine protease, at 1.7 A resolution. Structure 5:813–824 http://dx.doi.org/10.1016/S0969-2126(97)00235-9.
173. Vath GM, Earhart CA, Monie DD, Iandolo JJ, Schlievert PM, Ohlendorf DH. 1999. The crystal structure of exfoliative toxin B: a superantigen with enzymatic activity. Biochemistry 38:10239–10246 http://dx.doi.org/10.1021/bi990721e. [PubMed]
174. Vath GM, Earhart CA, Rago JV, Kim MH, Bohach GA, Schlievert PM, Ohlendorf DH. 1997. The structure of the superantigen exfoliative toxin A suggests a novel regulation as a serine protease. Biochemistry 36:1559–1566 http://dx.doi.org/10.1021/bi962614f. [PubMed]
175. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. 2000. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 6:1275–1277 http://dx.doi.org/10.1038/81385. [PubMed]
176. Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. 2002. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol 118:845–850 http://dx.doi.org/10.1046/j.1523-1747.2002.01751.x. [PubMed]
177. Hanakawa Y, Selwood T, Woo D, Lin C, Schechter NM, Stanley JR. 2003. Calcium-dependent conformation of desmoglein 1 is required for its cleavage by exfoliative toxin. J Invest Dermatol 121:383–389 http://dx.doi.org/10.1046/j.1523-1747.2003.12362.x. [PubMed]
178. Hanakawa Y, Schechter NM, Lin C, Nishifuji K, Amagai M, Stanley JR. 2004. Enzymatic and molecular characteristics of the efficiency and specificity of exfoliative toxin cleavage of desmoglein 1. J Biol Chem 279:5268–5277 http://dx.doi.org/10.1074/jbc.M311087200. [PubMed]
179. Nishifuji K, Sugai M, Amagai M. 2008. Staphylococcal exfoliative toxins: “molecular scissors” of bacteria that attack the cutaneous defense barrier in mammals. J Dermatol Sci 49:21–31 http://dx.doi.org/10.1016/j.jdermsci.2007.05.007. [PubMed]
180. Nagasaka T, Nishifuji K, Ota T, Whittock NV, Amagai M. 2004. Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scalded skin syndrome. J Clin Invest 114:1484–1492 http://dx.doi.org/10.1172/JCI20480. [PubMed]
181. Becker K, Heilmann C, Peters G. 2014. Coagulase-negative staphylococci. Clin Microbiol Rev 27:870–926 http://dx.doi.org/10.1128/CMR.00109-13. [PubMed]
182. Loeb L. 1903. The influence of certain bacteria on the coagulation of the blood. J Med Res 10:407–419. [PubMed]
183. Bjerketorp J, Jacobsson K, Frykberg L. 2004. The von Willebrand factor-binding protein (vWbp) of Staphylococcus aureus is a coagulase. FEMS Microbiol Lett 234:309–314 http://dx.doi.org/10.1111/j.1574-6968.2004.tb09549.x. [PubMed]
184. Watanabe S, Ito T, Takeuchi F, Endo M, Okuno E, Hiramatsu K. 2005. Structural comparison of ten serotypes of staphylocoagulases in Staphylococcus aureus. J Bacteriol 187:3698–3707 http://dx.doi.org/10.1128/JB.187.11.3698-3707.2005. [PubMed]
185. McCarthy AJ, Lindsay JA. 2010. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol 10:173 http://dx.doi.org/10.1186/1471-2180-10-173. [PubMed]
186. Viana D, Blanco J, Tormo-Más MA, Selva L, Guinane CM, Baselga R, Corpa J, Lasa I, Novick RP, Fitzgerald JR, Penadés JR. 2010. Adaptation of Staphylococcus aureus to ruminant and equine hosts involves SaPI-carried variants of von Willebrand factor-binding protein. Mol Microbiol 77:1583–1594 http://dx.doi.org/10.1111/j.1365-2958.2010.07312.x. [PubMed]
187. Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM, Schneewind O. 2010. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog 6:e1001036 http://dx.doi.org/10.1371/journal.ppat.1001036. [PubMed]
188. McAdow M, Missiakas DM, Schneewind O. 2012. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun 4:141–148 http://dx.doi.org/10.1159/000333447. [PubMed]
189. Friedrich R, Panizzi P, Fuentes-Prior P, Richter K, Verhamme I, Anderson PJ, Kawabata S, Huber R, Bode W, Bock PE. 2003. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425:535–539 http://dx.doi.org/10.1038/nature01962. [PubMed]
190. Bjerketorp J, Nilsson M, Ljungh A, Flock JI, Jacobsson K, Frykberg L. 2002. A novel von Willebrand factor binding protein expressed by Staphylococcus aureus. Microbiology 148:2037–2044 http://dx.doi.org/10.1099/00221287-148-7-2037. [PubMed]
191. Kroh HK, Panizzi P, Bock PE. 2009. Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. Proc Natl Acad Sci U S A 106:7786–7791 http://dx.doi.org/10.1073/pnas.0811750106. [PubMed]
192. Bock PE, Panizzi P, Verhamme IM. 2007. Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost 5(Suppl 1) :81–94 http://dx.doi.org/10.1111/j.1538-7836.2007.02496.x. [PubMed]
193. Peetermans M, Verhamme P, Vanassche T. 2015. Coagulase activity by Staphylococcus aureus: a potential target for therapy? Semin Thromb Hemost 41:433–444 http://dx.doi.org/10.1055/s-0035-1549849. [PubMed]
194. Vanassche T, Verhaegen J, Peetermans WE, Hoylaerts MF, Verhamme P. 2010. Dabigatran inhibits Staphylococcus aureus coagulase activity. J Clin Microbiol 48:4248–4250 http://dx.doi.org/10.1128/JCM.00896-10. [PubMed]
195. Hijikata-Okunomiya A, Kataoka N. 2003. Argatroban inhibits staphylothrombin. J Thromb Haemost 1:2060–2061 http://dx.doi.org/10.1046/j.1538-7836.2003.00346.x. [PubMed]
196. Thomer L, Emolo C, Thammavongsa V, Kim HK, McAdow ME, Yu W, Kieffer M, Schneewind O, Missiakas D. 2016. Antibodies against a secreted product of Staphylococcus aureus trigger phagocytic killing. J Exp Med 213:293–301 http://dx.doi.org/10.1084/jem.20150074. [PubMed]
197. Loof TG, Goldmann O, Naudin C, Mörgelin M, Neumann Y, Pils MC, Foster SJ, Medina E, Herwald H. 2015. Staphylococcus aureus-induced clotting of plasma is an immune evasion mechanism for persistence within the fibrin network. Microbiology 161:621–627 http://dx.doi.org/10.1099/mic.0.000019. [PubMed]
198. Ekstedt RD, Yotis WW. 1960. Studies on staphylococci. II. Effect of coagulase on the virulence of coagulase negative strains. J Bacteriol 80:496–500. [PubMed]
199. Zapotoczna M, McCarthy H, Rudkin JK, O’Gara JP, O’Neill E. 2015. An essential role for coagulase in Staphylococcus aureus biofilm development reveals new therapeutic possibilities for device-related infections. J Infect Dis 212:1883–1893 http://dx.doi.org/10.1093/infdis/jiv319. [PubMed]
200. Guggenberger C, Wolz C, Morrissey JA, Heesemann J. 2012. Two distinct coagulase-dependent barriers protect Staphylococcus aureus from neutrophils in a three dimensional in vitro infection model. PLoS Pathog 8:e1002434 http://dx.doi.org/10.1371/journal.ppat.1002434. [PubMed]
201. de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, Heezius EC, Poppelier MJ, Van Kessel KP, van Strijp JA. 2004. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 199:687–695 http://dx.doi.org/10.1084/jem.20031636. [PubMed]
202. Coleman DC, Sullivan DJ, Russell RJ, Arbuthnott JP, Carey BF, Pomeroy HM. 1989. Staphylococcus aureus bacteriophages mediating the simultaneous lysogenic conversion of beta-lysin, staphylokinase and enterotoxin A: molecular mechanism of triple conversion. J Gen Microbiol 135:1679–1697. [PubMed]
203. Sako T, Sawaki S, Sakurai T, Ito S, Yoshizawa Y, Kondo I. 1983. Cloning and expression of the staphylokinase gene of Staphylococcus aureus in Escherichia coli. Mol Gen Genet 190:271–277 http://dx.doi.org/10.1007/BF00330650. [PubMed]
204. Kondo I, Fujise K. 1977. Serotype B staphylococcal bacteriophage singly converting staphylokinase. Infect Immun 18:266–272. [PubMed]
205. Bokarewa MI, Jin T, Tarkowski A. 2006. Staphylococcus aureus: staphylokinase. Int J Biochem Cell Biol 38:504–509 http://dx.doi.org/10.1016/j.biocel.2005.07.005. [PubMed]
206. Behnke D, Gerlach D. 1987. Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase: a bacterial plasminogen activator. Mol Gen Genet 210:528–534 http://dx.doi.org/10.1007/BF00327208. [PubMed]
207. Horii T, Yokoyama K, Barua S, Odagiri T, Futamura N, Hasegawa T, Ohta M. 2000. The staphylokinase gene is located in the structural gene encoding N-acetylmuramyl- l-alanine amidase in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 185:221–224.
208. Borchardt SA, Babwah AV, Jayaswal RK. 1993. Sequence analysis of the region downstream from a peptidoglycan hydrolase-encoding gene from Staphylococcus aureus NCTC8325. Gene 137:253–258 http://dx.doi.org/10.1016/0378-1119(93)90016-V.
209. Rabijns A, De Bondt HL, De Ranter C. 1997. Three-dimensional structure of staphylokinase, a plasminogen activator with therapeutic potential. Nat Struct Biol 4:357–360 http://dx.doi.org/10.1038/nsb0597-357. [PubMed]
210. Grella DK, Castellino FJ. 1997. Activation of human plasminogen by staphylokinase. Direct evidence that preformed plasmin is necessary for activation to occur. Blood 89:1585–1589. [PubMed]
211. Lijnen HR, Van Hoef B, Collen D. 1993. Interaction of staphylokinase with different molecular forms of plasminogen. Eur J Biochem 211:91–97 http://dx.doi.org/10.1111/j.1432-1033.1993.tb19873.x. [PubMed]
212. Collen D, Schlott B, Engelborghs Y, Van Hoef B, Hartmann M, Lijnen HR, Behnke D. 1993. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem 268:8284–8289. [PubMed]
213. Schlott B, Gührs KH, Hartmann M, Röcker A, Collen D. 1997. Staphylokinase requires NH2-terminal proteolysis for plasminogen activation. J Biol Chem 272:6067–6072 http://dx.doi.org/10.1074/jbc.272S.9.6067. [PubMed]
214. Gase A, Hartmann M, Gührs KH, Röcker A, Collen D, Behnke D, Schlott B. 1996. Functional significance of NH2- and COOH-terminal regions of staphylokinase in plasminogen activation. Thromb Haemost 76:755–760 http://dx.doi.org/10.1055/s-0038-1650656. [PubMed]
215. Parry MA, Fernandez-Catalan C, Bergner A, Huber R, Hopfner KP, Schlott B, Gührs KH, Bode W. 1998. The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action. Nat Struct Biol 5:917–923 http://dx.doi.org/10.1038/2359. [PubMed]
216. Lijnen HR, Van Hoef B, De Cock F, Okada K, Ueshima S, Matsuo O, Collen D. 1991. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 266:11826–11832. [PubMed]
217. Rooijakkers SH, van Wamel WJ, Ruyken M, van Kessel KP, van Strijp JA. 2005. Anti-opsonic properties of staphylokinase. Microbes Infect 7:476–484 http://dx.doi.org/10.1016/j.micinf.2004.12.014. [PubMed]
218. Santala A, Saarinen J, Kovanen P, Kuusela P. 1999. Activation of interstitial collagenase, MMP-1, by Staphylococcus aureus cells having surface-bound plasmin: a novel role of plasminogen receptors of bacteria. FEBS Lett 461:153–156 http://dx.doi.org/10.1016/S0014-5793(99)01440-4.
219. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. 2004. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 172:1169–1176 http://dx.doi.org/10.4049/jimmunol.172.2.1169. [PubMed]
220. Braff MH, Jones AL, Skerrett SJ, Rubens CE. 2007. Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis. J Infect Dis 195:1365–1372 http://dx.doi.org/10.1086/513277. [PubMed]
221. Kwiecinski J, Peetermans M, Liesenborghs L, Na M, Björnsdottir H, Zhu X, Jacobsson G, Johansson BR, Geoghegan JA, Foster TJ, Josefsson E, Bylund J, Verhamme P, Jin T. 2016. Staphylokinase control of Staphylococcus aureus biofilm formation and detachment through host plasminogen activation. J Infect Dis 213:139–148 http://dx.doi.org/10.1093/infdis/jiv360. [PubMed]
222. Peetermans M, Vanassche T, Liesenborghs L, Claes J, Vande Velde G, Kwiecinksi J, Jin T, De Geest B, Hoylaerts MF, Lijnen RH, Verhamme P. 2014. Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections. BMC Microbiol 14:310 http://dx.doi.org/10.1186/s12866-014-0310-7. [PubMed]
223. Kwiecinski J, Jacobsson G, Karlsson M, Zhu X, Wang W, Bremell T, Josefsson E, Jin T. 2013. Staphylokinase promotes the establishment of Staphylococcus aureus skin infections while decreasing disease severity. J Infect Dis 208:990–999 http://dx.doi.org/10.1093/infdis/jit288. [PubMed]
224. Cunningham L, Catlin BW, de Garilhe MP. 1956. A deoxyribonuclease of micrococcus pyogenes1. J Am Chem Soc 78:4642–4645 http://dx.doi.org/10.1021/ja01599a031.
225. Cuatrecasas P, Fuchs S, Anfinsen CB. 1967. Catalytic properties and specificity of the extracellular nuclease of Staphylococcus aureus. J Biol Chem 242:1541–1547. [PubMed]
226. Tang J, Zhou R, Shi X, Kang M, Wang H, Chen H. 2008. Two thermostable nucleases coexisted in Staphylococcus aureus: evidence from mutagenesis and in vitro expression. FEMS Microbiol Lett 284:176–183 http://dx.doi.org/10.1111/j.1574-6968.2008.01194.x. [PubMed]
227. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani-Ui Y, Takahashi NK, Sawano T, Inoue R, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K. 2001. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357:1225–1240 http://dx.doi.org/10.1016/S0140-6736(00)04403-2.
228. Kiedrowski MR, Crosby HA, Hernandez FJ, Malone CL, McNamara JO II, Horswill AR. 2014. Staphylococcus aureus Nuc2 is a functional, surface-attached extracellular nuclease. PLoS One 9:e95574 http://dx.doi.org/10.1371/journal.pone.0095574. [PubMed]
229. Davis A, Moore IB, Parker DS, Taniuchi H. 1977. Nuclease B. A possible precursor of nuclease A, an extracellular nuclease of Staphylococcus aureus. J Biol Chem 252:6544–6553. [PubMed]
230. Kiedrowski MR, Kavanaugh JS, Malone CL, Mootz JM, Voyich JM, Smeltzer MS, Bayles KW, Horswill AR. 2011. Nuclease modulates biofilm formation in community-associated methicillin-resistant Staphylococcus aureus. PLoS One 6:e26714 http://dx.doi.org/10.1371/journal.pone.0026714. [PubMed]
231. Mann EE, Rice KC, Boles BR, Endres JL, Ranjit D, Chandramohan L, Tsang LH, Smeltzer MS, Horswill AR, Bayles KW. 2009. Modulation of eDNA release and degradation affects Staphylococcus aureus biofilm maturation. PLoS One 4:e5822 http://dx.doi.org/10.1371/journal.pone.0005822. [PubMed]
232. Olson ME, Nygaard TK, Ackermann L, Watkins RL, Zurek OW, Pallister KB, Griffith S, Kiedrowski MR, Flack CE, Kavanaugh JS, Kreiswirth BN, Horswill AR, Voyich JM. 2013. Staphylococcus aureus nuclease is an SaeRS-dependent virulence factor. Infect Immun 81:1316–1324 http://dx.doi.org/10.1128/IAI.01242-12. [PubMed]
233. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. 2004. Neutrophil extracellular traps kill bacteria. Science 303:1532–1535 http://dx.doi.org/10.1126/science.1092385. [PubMed]
234. Berends ET, Horswill AR, Haste NM, Monestier M, Nizet V, von Köckritz-Blickwede M. 2010. Nuclease expression by Staphylococcus aureus facilitates escape from neutrophil extracellular traps. J Innate Immun 2:576–586 http://dx.doi.org/10.1159/000319909. [PubMed]
235. Thammavongsa V, Missiakas DM, Schneewind O. 2013. Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death. Science 342:863–866 http://dx.doi.org/10.1126/science.1242255. [PubMed]
236. Arvidson S. 1973. Studies on extracellular proteolytic enzymes from Staphylococcus aureus. II. Isolation and characterization of an EDTA-sensitive protease. Biochim Biophys Acta 302:149–157 http://dx.doi.org/10.1016/0005-2744(73)90017-X.
237. Arvidson S, Holme T, Lindholm B. 1972. The formation of extracellular proteolytic enzymes by Staphylococcus aureus. Acta Pathol Microbiol Scand B Microbiol Immunol 80:835–844. [PubMed]
238. Banbula A, Potempa J, Travis J, Fernandez-Catalán C, Mann K, Huber R, Bode W, Medrano F. 1998. Amino-acid sequence and three-dimensional structure of the Staphylococcus aureus metalloproteinase at 1.72 A resolution. Structure 6:1185–1193 http://dx.doi.org/10.1016/S0969-2126(98)00118-X.
239. Potempa J, Dubin A, Korzus G, Travis J. 1988. Degradation of elastin by a cysteine proteinase from Staphylococcus aureus. J Biol Chem 263:2664–2667. [PubMed]
240. Nickerson NN, Joag V, McGavin MJ. 2008. Rapid autocatalytic activation of the M4 metalloprotease aureolysin is controlled by a conserved N-terminal fungalysin-thermolysin-propeptide domain. Mol Microbiol 69:1530–1543 http://dx.doi.org/10.1111/j.1365-2958.2008.06384.x. [PubMed]
241. Bjoörklind A, Jörnvall H. 1974. Substrate specificity of three different extracellular proteolytic enzymes from Staphylococcus aureus. Biochim Biophys Acta 370:524–529 http://dx.doi.org/10.1016/0005-2744(74)90113-2.
242. Drapeau GR. 1978. Role of metalloprotease in activation of the precursor of staphylococcal protease. J Bacteriol 136:607–613. [PubMed]
243. Nickerson NN, Prasad L, Jacob L, Delbaere LT, McGavin MJ. 2007. Activation of the SspA serine protease zymogen of Staphylococcus aureus proceeds through unique variations of a trypsinogen-like mechanism and is dependent on both autocatalytic and metalloprotease-specific processing. J Biol Chem 282:34129–34138 http://dx.doi.org/10.1074/jbc.M705672200. [PubMed]
244. McAleese FM, Walsh EJ, Sieprawska M, Potempa J, Foster TJ. 2001. Loss of clumping factor B fibrinogen binding activity by Staphylococcus aureus involves cessation of transcription, shedding and cleavage by metalloprotease. J Biol Chem 276:29969–29978 http://dx.doi.org/10.1074/jbc.M102389200. [PubMed]
245. Gonzalez DJ, Okumura CY, Hollands A, Kersten R, Akong-Moore K, Pence MA, Malone CL, Derieux J, Moore BS, Horswill AR, Dixon JE, Dorrestein PC, Nizet V. 2012. Novel phenol-soluble modulin derivatives in community-associated methicillin-resistant Staphylococcus aureus identified through imaging mass spectrometry. J Biol Chem 287:13889–13898 http://dx.doi.org/10.1074/jbc.M112.349860. [PubMed]
246. Cassat JE, Hammer ND, Campbell JP, Benson MA, Perrien DS, Mrak LN, Smeltzer MS, Torres VJ, Skaar EP. 2013. A secreted bacterial protease tailors the Staphylococcus aureus virulence repertoire to modulate bone remodeling during osteomyelitis. Cell Host Microbe 13:759–772 http://dx.doi.org/10.1016/j.chom.2013.05.003. [PubMed]
247. Sieprawska-Lupa M, Mydel P, Krawczyk K, Wójcik K, Puklo M, Lupa B, Suder P, Silberring J, Reed M, Pohl J, Shafer W, McAleese F, Foster T, Travis J, Potempa J. 2004. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 48:4673–4679 http://dx.doi.org/10.1128/AAC.48.12.4673-4679.2004. [PubMed]
248. Potempa J, Watorek W, Travis J. 1986. The inactivation of human plasma alpha 1-proteinase inhibitor by proteinases from Staphylococcus aureus. J Biol Chem 261:14330–14334. [PubMed]
249. Potempa J, Fedak D, Dubin A, Mast A, Travis J. 1991. Proteolytic inactivation of alpha-1-anti-chymotrypsin. Sites of cleavage and generation of chemotactic activity. J Biol Chem 266:21482–21487. [PubMed]
250. Laarman AJ, Ruyken M, Malone CL, van Strijp JA, Horswill AR, Rooijakkers SH. 2011. Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. J Immunol 186:6445–6453 http://dx.doi.org/10.4049/jimmunol.1002948. [PubMed]
251. Holers VM. 2014. Complement and its receptors: new insights into human disease. Annu Rev Immunol 32:433–459 http://dx.doi.org/10.1146/annurev-immunol-032713-120154.
252. Beaufort N, Wojciechowski P, Sommerhoff CP, Szmyd G, Dubin G, Eick S, Kellermann J, Schmitt M, Potempa J, Magdolen V. 2008. The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Biochem J 410:157–165 http://dx.doi.org/10.1042/BJ20070650.
253. Wegrzynowicz Z, Heczko PB, Drapeau GR, Jeljaszewicz J, Pulverer G. 1980. Prothrombin activation by a metalloprotease from Staphylococcus aureus. J Clin Microbiol 12:138–139.
254. Burlak C, Hammer CH, Robinson MA, Whitney AR, McGavin MJ, Kreiswirth BN, Deleo FR. 2007. Global analysis of community-associated methicillin-resistant Staphylococcus aureus exoproteins reveals molecules produced in vitro and during infection. Cell Microbiol 9:1172–1190 http://dx.doi.org/10.1111/j.1462-5822.2006.00858.x.
255. Rice K, Peralta R, Bast D, de Azavedo J, McGavin MJ. 2001. Description of staphylococcus serine protease (ssp) operon in Staphylococcus aureus and nonpolar inactivation of sspA-encoded serine protease. Infect Immun 69:159–169 http://dx.doi.org/10.1128/IAI.69.1.159-169.2001.
256. Drapeau GR, Boily Y, Houmard J. 1972. Purification and properties of an extracellular protease of Staphylococcus aureus. J Biol Chem 247:6720–6726.
257. Arvidson S, Holme T, Lindholm B. 1973. Studies on extracellular proteolytic enzymes from Staphylococcus aureus. I. Purification and characterization of one neutral and one alkaline protease. Biochim Biophys Acta 302:135–148 http://dx.doi.org/10.1016/0005-2744(73)90016-8.
258. Prasad L, Leduc Y, Hayakawa K, Delbaere LT. 2004. The structure of a universally employed enzyme: V8 protease from Staphylococcus aureus. Acta Crystallogr D Biol Crystallogr 60:256–259 http://dx.doi.org/10.1107/S090744490302599X.
259. Yoshikawa K, Tsuzuki H, Fujiwara T, Nakamura E, Iwamoto H, Matsumoto K, Shin M, Yoshida N, Teraoka H. 1992. Purification, characterization and gene cloning of a novel glutamic acid-specific endopeptidase from Staphylococcus aureus ATCC 12600. Biochim Biophys Acta 1121:221–228 http://dx.doi.org/10.1016/0167-4838(92)90358-K.
260. Drapeau GR. 1978. Unusual COOH-terminal structure of staphylococcal protease. J Biol Chem 253:5899–5901.
261. Carmona C, Gray GL. 1987. Nucleotide sequence of the serine protease gene of Staphylococcus aureus, strain V8. Nucleic Acids Res 15:6757 http://dx.doi.org/10.1093/nar/15.16.6757.
262. Yabuta M, Ochi N, Ohsuye K. 1995. Hyperproduction of a recombinant fusion protein of Staphylococcus aureus V8 protease in Escherichia coli and its processing by OmpT protease to release an active V8 protease derivative. Appl Microbiol Biotechnol 44:118–125 http://dx.doi.org/10.1007/BF00164490.
263. McGavin MJ, Zahradka C, Rice K, Scott JE. 1997. Modification of the Staphylococcus aureus fibronectin binding phenotype by V8 protease. Infect Immun 65:2621–2628.
264. Karlsson A, Saravia-Otten P, Tegmark K, Morfeldt E, Arvidson S. 2001. Decreased amounts of cell wall-associated protein A and fibronectin-binding proteins in Staphylococcus aureus sarA mutants due to up-regulation of extracellular proteases. Infect Immun 69:4742–4748 http://dx.doi.org/10.1128/IAI.69.8.4742-4748.2001.
265. Murphy J, Ramezanpour M, Stach N, Dubin G, Psaltis AJ, Wormald PJ, Vreugde S. 2017. Staphylococcus aureus V8 protease disrupts the integrity of the airway epithelial barrier and impairs IL-6 production in vitro. Laryngoscope 128:E8–E15.
266. Prokesová L, Potuzníková B, Potempa J, Zikán J, Radl J, Hachová L, Baran K, Porwit-Bobr Z, John C. 1992. Cleavage of human immunoglobulins by serine proteinase from Staphylococcus aureus. Immunol Lett 31:259–265 http://dx.doi.org/10.1016/0165-2478(92)90124-7.
267. Rousseaux J, Rousseaux-Prévost R, Bazin H, Biserte G. 1983. Proteolysis of rat IgG subclasses by Staphylococcus aureus V8 proteinase. Biochim Biophys Acta 748:205–212 http://dx.doi.org/10.1016/0167-4838(83)90296-0.
268. Hirasawa Y, Takai T, Nakamura T, Mitsuishi K, Gunawan H, Suto H, Ogawa T, Wang XL, Ikeda S, Okumura K, Ogawa H. 2010. Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction. J Invest Dermatol 130:614–617 http://dx.doi.org/10.1038/jid.2009.257.
269. Shaw L, Golonka E, Potempa J, Foster SJ. 2004. The role and regulation of the extracellular proteases of Staphylococcus aureus. Microbiology 150:217–228 http://dx.doi.org/10.1099/mic.0.26634-0.
270. Chan PF, Foster SJ. 1998. Role of SarA in virulence determinant production and environmental signal transduction in Staphylococcus aureus. J Bacteriol 180:6232–6241.
271. Takeuchi S, Matsunaga K, Inubushi S, Higuchi H, Imaizumi K, Kaidoh T. 2002. Structural gene and strain specificity of a novel cysteine protease produced by Staphylococcus aureus isolated from a diseased chicken. Vet Microbiol 89:201–210 http://dx.doi.org/10.1016/S0378-1135(02)00171-2.
272. Kalińska M, Kantyka T, Greenbaum DC, Larsen KS, Władyka B, Jabaiah A, Bogyo M, Daugherty PS, Wysocka M, Jaros M, Lesner A, Rolka K, Schaschke N, Stennicke H, Dubin A, Potempa J, Dubin G. 2012. Substrate specificity of Staphylococcus aureus cysteine proteases: staphopains A, B and C. Biochimie 94:318–327 http://dx.doi.org/10.1016/j.biochi.2011.07.020.
273. Rzychon M, Sabat A, Kosowska K, Potempa J, Dubin A. 2003. Staphostatins: an expanding new group of proteinase inhibitors with a unique specificity for the regulation of staphopains, Staphylococcus spp. cysteine proteinases. Mol Microbiol 49:1051–1066 http://dx.doi.org/10.1046/j.1365-2958.2003.03613.x.
274. Massimi I, Park E, Rice K, Muller-Esterl W, Sauder D, McGavin MJ. 2002. Identification of a novel maturation mechanism and restricted substrate specificity for the SspB cysteine protease of Staphylococcus aureus. J Biol Chem 277:41770–41777 http://dx.doi.org/10.1074/jbc.M207162200.
275. Nickerson N, Ip J, Passos DT, McGavin MJ. 2010. Comparison of staphopain A (ScpA) and B (SspB) precursor activation mechanisms reveals unique secretion kinetics of proSspB (staphopain B), and a different interaction with its cognate Staphostatin, SspC. Mol Microbiol 75:161–177 http://dx.doi.org/10.1111/j.1365-2958.2009.06974.x.
276. Filipek R, Potempa J, Bochtler M. 2005. A comparison of staphostatin B with standard mechanism serine protease inhibitors. J Biol Chem 280:14669–14674 http://dx.doi.org/10.1074/jbc.M411792200.
277. Hofmann B, Schomburg D, Hecht HJ. 1993. Crystal structure of a thiol proteinase from Staphylococcus aureus V-8 in the E-64 inhibitor complex. Acta Crystallogr A 49(s1) :102 http://dx.doi.org/10.1107/S0108767378097081.
278. Kantyka T, Shaw LN, Potempa J. 2011. Papain-like proteases of Staphylococcus aureus. Adv Exp Med Biol 712:1–14 http://dx.doi.org/10.1007/978-1-4419-8414-2_1.
279. Kantyka T, Pyrc K, Gruca M, Smagur J, Plaza K, Guzik K, Zeglen S, Ochman M, Potempa J. 2013. Staphylococcus aureus proteases degrade lung surfactant protein A potentially impairing innate immunity of the lung. J Innate Immun 5:251–260 http://dx.doi.org/10.1159/000345417.
280. Laarman AJ, Mijnheer G, Mootz JM, van Rooijen WJ, Ruyken M, Malone CL, Heezius EC, Ward R, Milligan G, van Strijp JA, de Haas CJ, Horswill AR, van Kessel KP, Rooijakkers SH. 2012. Staphylococcus aureus staphopain A inhibits CXCR2-dependent neutrophil activation and chemotaxis. EMBO J 31:3607–3619 http://dx.doi.org/10.1038/emboj.2012.212.
281. Imamura T, Tanase S, Szmyd G, Kozik A, Travis J, Potempa J. 2005. Induction of vascular leakage through release of bradykinin and a novel kinin by cysteine proteinases from Staphylococcus aureus. J Exp Med 201:1669–1676 http://dx.doi.org/10.1084/jem.20042041.
282. Sonesson A, Przybyszewska K, Eriksson S, Mörgelin M, Kjellström S, Davies J, Potempa J, Schmidtchen A. 2017. Identification of bacterial biofilm and the Staphylococcus aureus derived protease, staphopain, on the skin surface of patients with atopic dermatitis. Sci Rep 7:8689 http://dx.doi.org/10.1038/s41598-017-08046-2.
283. Smagur J, Guzik K, Bzowska M, Kuzak M, Zarebski M, Kantyka T, Walski M, Gajkowska B, Potempa J. 2009. Staphylococcal cysteine protease staphopain B (SspB) induces rapid engulfment of human neutrophils and monocytes by macrophages. Biol Chem 390:361–371 http://dx.doi.org/10.1515/BC.2009.042.
284. Smagur J, Guzik K, Magiera L, Bzowska M, Gruca M, Thøgersen IB, Enghild JJ, Potempa J. 2009. A new pathway of staphylococcal pathogenesis: apoptosis-like death induced by staphopain B in human neutrophils and monocytes. J Innate Immun 1:98–108 http://dx.doi.org/10.1159/000181014.
285. Kulig P, Zabel BA, Dubin G, Allen SJ, Ohyama T, Potempa J, Handel TM, Butcher EC, Cichy J. 2007. Staphylococcus aureus-derived staphopain B, a potent cysteine protease activator of plasma chemerin. J Immunol 178:3713–3720 http://dx.doi.org/10.4049/jimmunol.178.6.3713.
286. Kubica M, Guzik K, Koziel J, Zarebski M, Richter W, Gajkowska B, Golda A, Maciag-Gudowska A, Brix K, Shaw L, Foster T, Potempa J. 2008. A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS One 3:e1409 http://dx.doi.org/10.1371/journal.pone.0001409.
287. Schindler D, Gutierrez MG, Beineke A, Rauter Y, Rohde M, Foster S, Goldmann O, Medina E. 2012. Dendritic cells are central coordinators of the host immune response to Staphylococcus aureus bloodstream infection. Am J Pathol 181:1327–1337 http://dx.doi.org/10.1016/j.ajpath.2012.06.039.
288. Loughran AJ, Atwood DN, Anthony AC, Harik NS, Spencer HJ, Beenken KE, Smeltzer MS. 2014. Impact of individual extracellular proteases on Staphylococcus aureus biofilm formation in diverse clinical isolates and their isogenic sarA mutants. Microbiologyopen 3:897–909 http://dx.doi.org/10.1002/mbo3.214.
289. Mootz JM, Malone CL, Shaw LN, Horswill AR. 2013. Staphopains modulate Staphylococcus aureus biofilm integrity. Infect Immun 81:3227–3238 http://dx.doi.org/10.1128/IAI.00377-13.
290. Ohbayashi T, Irie A, Murakami Y, Nowak M, Potempa J, Nishimura Y, Shinohara M, Imamura T. 2011. Degradation of fibrinogen and collagen by staphopains, cysteine proteases released from Staphylococcus aureus. Microbiology 157:786–792 http://dx.doi.org/10.1099/mic.0.044503-0.
291. Kantyka T, Plaza K, Koziel J, Florczyk D, Stennicke HR, Thogersen IB, Enghild JJ, Silverman GA, Pak SC, Potempa J. 2011. Inhibition of Staphylococcus aureus cysteine proteases by human serpin potentially limits staphylococcal virulence. Biol Chem 392:483–489 http://dx.doi.org/10.1515/bc.2011.044.
292. Rzychon M, Filipek R, Sabat A, Kosowska K, Dubin A, Potempa J, Bochtler M. 2003. Staphostatins resemble lipocalins, not cystatins in fold. Protein Sci 12:2252–2256 http://dx.doi.org/10.1110/ps.03247703.
293. Filipek R, Rzychon M, Oleksy A, Gruca M, Dubin A, Potempa J, Bochtler M. 2003. The Staphostatin-staphopain complex: a forward binding inhibitor in complex with its target cysteine protease. J Biol Chem 278:40959–40966 http://dx.doi.org/10.1074/jbc.M302926200.
294. Shaw LN, Golonka E, Szmyd G, Foster SJ, Travis J, Potempa J. 2005. Cytoplasmic control of premature activation of a secreted protease zymogen: deletion of staphostatin B (SspC) in Staphylococcus aureus 8325-4 yields a profound pleiotropic phenotype. J Bacteriol 187:1751–1762 http://dx.doi.org/10.1128/JB.187.5.1751-1762.2005.
295. Rieneck K, Renneberg J, Diamant M, Gutschik E, Bendtzen K. 1997. Molecular cloning and expression of a novel Staphylococcus aureus antigen. Biochim Biophys Acta 1350:128–132 http://dx.doi.org/10.1016/S0167-4781(96)00216-3.
296. Reed SB, Wesson CA, Liou LE, Trumble WR, Schlievert PM, Bohach GA, Bayles KW. 2001. Molecular characterization of a novel Staphylococcus aureus serine protease operon. Infect Immun 69:1521–1527 http://dx.doi.org/10.1128/IAI.69.3.1521-1527.2001.
297. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. 2008. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands. J Bacteriol 190:300–310 http://dx.doi.org/10.1128/JB.01000-07.
298. Dubin G, Stec-Niemczyk J, Kisielewska M, Pustelny K, Popowicz GM, Bista M, Kantyka T, Boulware KT, Stennicke HR, Czarna A, Phopaisarn M, Daugherty PS, Thøgersen IB, Enghild JJ, Thornberry N, Dubin A, Potempa J. 2008. Enzymatic activity of the Staphylococcus aureus SplB serine protease is induced by substrates containing the sequence Trp-Glu-Leu-Gln. J Mol Biol 379:343–356 http://dx.doi.org/10.1016/j.jmb.2008.03.059.
299. Stec-Niemczyk J, Pustelny K, Kisielewska M, Bista M, Boulware KT, Stennicke HR, Thogersen IB, Daugherty PS, Enghild JJ, Baczynski K, Popowicz GM, Dubin A, Potempa J, Dubin G. 2009. Structural and functional characterization of SplA, an exclusively specific protease of Staphylococcus aureus. Biochem J 419:555–564 http://dx.doi.org/10.1042/BJ20081351.
300. Zdzalik M, Kalinska M, Wysocka M, Stec-Niemczyk J, Cichon P, Stach N, Gruba N, Stennicke HR, Jabaiah A, Markiewicz M, Kedracka-Krok S, Wladyka B, Daugherty PS, Lesner A, Rolka K, Dubin A, Potempa J, Dubin G. 2013. Biochemical and structural characterization of SplD protease from Staphylococcus aureus. PLoS One 8:e76812 http://dx.doi.org/10.1371/journal.pone.0076812.
301. Popowicz GM, Dubin G, Stec-Niemczyk J, Czarny A, Dubin A, Potempa J, Holak TA. 2006. Functional and structural characterization of Spl proteases from Staphylococcus aureus. J Mol Biol 358:270–279 http://dx.doi.org/10.1016/j.jmb.2006.01.098.
302. Paharik AE, Salgado-Pabon W, Meyerholz DK, White MJ, Schlievert PM, Horswill AR. 2016. The Spl serine proteases modulate Staphylococcus aureus protein production and virulence in a rabbit model of pneumonia. MSphere 1:1 http://dx.doi.org/10.1128/mSphere.00208-16.
303. Stentzel S, Teufelberger A, Nordengrun M, Kolata J, Schmidt F, van Crombruggen K, Michalik S, Kumpfmuller J, Tischer S, Schweder T, Hecker M, Engelmann S, Volker U, Krysko O, Bachert C, Broker BM. 2017. Staphylococcal serine protease-like proteins are pacemakers of allergic airway reactions to Staphylococcus aureus. J Allergy Clin Immunol 139:492–500.
304. Teufelberger AR, Nordengrun M, Braun H, Maes T, De Grove K, Holtappels G, O’Brien C, Provoost S, Hammad H, Goncalves A, Beyaert R, Declercq W, Vandenabeele P, Krysko DV, Broker BM, Bachert C, Krysko O. 2017. The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D. J Allergy Clin Immunol 141:549–559.
305. Laurent TC, Fraser JR. 1992. Hyaluronan. FASEB J 6:2397–2404 http://dx.doi.org/10.1096/fasebj.6.7.1563592.
306. Monslow J, Govindaraju P, Puré E. 2015. Hyaluronan: a functional and structural sweet spot in the tissue microenvironment. Front Immunol 6:231 http://dx.doi.org/10.3389/fimmu.2015.00231.
307. Lee-Sayer SS, Dong Y, Arif AA, Olsson M, Brown KL, Johnson P. 2015. The where, when, how, and why of hyaluronan binding by immune cells. Front Immunol 6:150 http://dx.doi.org/10.3389/fimmu.2015.00150.
308. Hynes WL, Walton SL. 2000. Hyaluronidases of Gram-positive bacteria. FEMS Microbiol Lett 183:201–207 http://dx.doi.org/10.1111/j.1574-6968.2000.tb08958.x.
309. Hart ME, Hart MJ, Roop AJ. 2009. Genotypic and phenotypic assessment of hyaluronidase among type strains of a select group of staphylococcal species. Int J Microbiol 2009:614371 http://dx.doi.org/10.1155/2009/614371.
310. Devriese LA, Hajek V, Oeding P, Meyer SA, Schleifer KH. 1978. Staphylococcushyicus (Sompolinsky 1953) comb nov and Staphylococcushyicus subsp chromogenes subsp nov. Int J Syst Bacteriol 28:482–490 http://dx.doi.org/10.1099/00207713-28-4-482.
311. Duran-Reynals F. 1933. Studies on a certain spreading factor existing in bacteria and its significance for bacterial invasiveness. J Exp Med 58:161–181 http://dx.doi.org/10.1084/jem.58.2.161.
312. Chain E, Duthie ES. 1940. Identity of hyaluronidase and spreading factor. Br J Exp Pathol 21:324–338.
313. Farrell AM, Taylor D, Holland KT. 1995. Cloning, nucleotide sequence determination and expression of the Staphylococcus aureus hyaluronate lyase gene. FEMS Microbiol Lett 130:81–85.
314. Makris G, Wright JD, Ingham E, Holland KT. 2004. The hyaluronate lyase of Staphylococcus aureus: a virulence factor? Microbiology 150:2005–2013 http://dx.doi.org/10.1099/mic.0.26942-0.
315. Ibberson CB, Jones CL, Singh S, Wise MC, Hart ME, Zurawski DV, Horswill AR. 2014. Staphylococcus aureus hyaluronidase is a CodY-regulated virulence factor. Infect Immun 82:4253–4264 http://dx.doi.org/10.1128/IAI.01710-14.
316. Ibberson CB, Parlet CP, Kwiecinski J, Crosby HA, Meyerholz DK, Horswill AR. 2016. Hyaluronan modulation impacts Staphylococcus aureus biofilm infection. Infect Immun 84:1917–1929 http://dx.doi.org/10.1128/IAI.01418-15. [PubMed]
317. Doery HM, Magnusson BJ, Gulasekharam J, Pearson JE. 1965. The properties of phospholipase enzymes in staphylococcal toxins. J Gen Microbiol 40:283–296 http://dx.doi.org/10.1099/00221287-40-2-283. [PubMed]
318. Magnusson BJ, Gulasekharam J, Doery HM. 1962. Phospholipase activity of staphylococcal toxin. Nature 196:270–271 http://dx.doi.org/10.1038/196270b0.
319. Daugherty S, Low MG. 1993. Cloning, expression, and mutagenesis of phosphatidylinositol-specific phospholipase C from Staphylococcus aureus: a potential staphylococcal virulence factor. Infect Immun 61:5078–5089. [PubMed]
320. Beining PR, Huff E, Prescott B, Theodore TS. 1975. Characterization of the lipids of mesosomal vesicles and plasma membranes from Staphylococcus aureus. J Bacteriol 121:137–143. [PubMed]
321. Goldstein R, Cheng J, Stec B, Roberts MF. 2012. Structure of the S. aureus PI-specific phospholipase C reveals modulation of active site access by a titratable π-cation latched loop. Biochemistry 51:2579–2587 http://dx.doi.org/10.1021/bi300057q. [PubMed]
322. Cheng J, Goldstein R, Stec B, Gershenson A, Roberts MF. 2012. Competition between anion binding and dimerization modulates Staphylococcus aureus phosphatidylinositol-specific phospholipase C enzymatic activity. J Biol Chem 287:40317–40327 http://dx.doi.org/10.1074/jbc.M112.395277. [PubMed]
323. Griffith OH, Ryan M. 1999. Bacterial phosphatidylinositol-specific phospholipase C: structure, function, and interaction with lipids. Biochim Biophys Acta 1441:237–254 http://dx.doi.org/10.1016/S1388-1981(99)00153-5.
324. Heinz DW, Essen LO, Williams RL. 1998. Structural and mechanistic comparison of prokaryotic and eukaryotic phosphoinositide-specific phospholipases C. J Mol Biol 275:635–650 http://dx.doi.org/10.1006/jmbi.1997.1490. [PubMed]
325. Flores-Díaz M, Monturiol-Gross L, Naylor C, Alape-Girón A, Flieger A. 2016. Bacterial sphingomyelinases and phospholipases as virulence factors. Microbiol Mol Biol Rev 80:597–628 http://dx.doi.org/10.1128/MMBR.00082-15. [PubMed]
326. Hänsch GM, Weller PF, Nicholson-Weller A. 1988. Release of C8 binding protein (C8bp) from the cell membrane by phosphatidylinositol-specific phospholipase C. Blood 72:1089–1092. [PubMed]
327. Medof ME, Walter EI, Roberts WL, Haas R, Rosenberry TL. 1986. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 25:6740–6747 http://dx.doi.org/10.1021/bi00370a003. [PubMed]
328. Schönermark S, Rauterberg EW, Shin ML, Löke S, Roelcke D, Hänsch GM. 1986. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 136:1772–1776. [PubMed]
329. Walter EI, Ratnoff WD, Long KE, Kazura JW, Medof ME. 1992. Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay-accelerating factor protein in cells. J Biol Chem 267:1245–1252. [PubMed]
330. White MJ, Boyd JM, Horswill AR, Nauseef WM. 2014. Phosphatidylinositol-specific phospholipase C contributes to survival of Staphylococcus aureus USA300 in human blood and neutrophils. Infect Immun 82:1559–1571 http://dx.doi.org/10.1128/IAI.01168-13. [PubMed]
331. Cadieux B, Vijayakumaran V, Bernards MA, McGavin MJ, Heinrichs DE. 2014. Role of lipase from community-associated methicillin-resistant Staphylococcus aureus strain USA300 in hydrolyzing triglycerides into growth-inhibitory free fatty acids. J Bacteriol 196:4044–4056 http://dx.doi.org/10.1128/JB.02044-14. [PubMed]
332. Rosenstein R, Götz F. 2000. Staphylococcal lipases: biochemical and molecular characterization. Biochimie 82:1005–1014 http://dx.doi.org/10.1016/S0300-9084(00)01180-9.
333. Götz F, Verheij HM, Rosenstein R. 1998. Staphylococcal lipases: molecular characterisation, secretion, and processing. Chem Phys Lipids 93:15–25 http://dx.doi.org/10.1016/S0009-3084(98)00025-5.
334. Nikoleit K, Rosenstein R, Verheij HM, Götz F. 1995. Comparative biochemical and molecular analysis of the Staphylococcus hyicus, Staphylococcus aureus and a hybrid lipase. Indication for a C-terminal phospholipase domain. Eur J Biochem 228:732–738 http://dx.doi.org/10.1111/j.1432-1033.1995.tb20317.x. [PubMed]
335. Rollof J, Normark S. 1992. In vivo processing of Staphylococcus aureus lipase. J Bacteriol 174:1844–1847 http://dx.doi.org/10.1128/jb.174.6.1844-1847.1992. [PubMed]
336. Demleitner G, Götz F. 1994. Evidence for importance of the Staphylococcus hyicus lipase pro-peptide in lipase secretion, stability and activity. FEMS Microbiol Lett 121:189–197 http://dx.doi.org/10.1111/j.1574-6968.1994.tb07098.x. [PubMed]
337. Liebl W, Götz F. 1986. Studies on lipase directed export of Escherichia coli beta-lactamase in Staphylococcus carnosus. Mol Gen Genet 204:166–173 http://dx.doi.org/10.1007/BF00330205. [PubMed]
338. Simons JW, Adams H, Cox RC, Dekker N, Götz F, Slotboom AJ, Verheij HM. 1996. The lipase from Staphylococcus aureus. Expression in Escherichia coli, large-scale purification and comparison of substrate specificity to Staphylococcus hyicus lipase. Eur J Biochem 242:760–769 http://dx.doi.org/10.1111/j.1432-1033.1996.0760r.x. [PubMed]
339. Rollof J, Hedström SA, Nilsson-Ehle P. 1987. Positional specificity and substrate preference of purified Staphylococcus aureus lipase. Biochim Biophys Acta 921:370–377 http://dx.doi.org/10.1016/0005-2760(87)90039-7.
340. Rollof J, Hedström SA, Nilsson-Ehle P. 1987. Lipolytic activity of Staphylococcus aureus strains from disseminated and localized infections. Acta Pathol Microbiol Immunol Scand [B] 95:109–113.
341. Rollof J, Braconier JH, Söderström C, Nilsson-Ehle P. 1988. Interference of Staphylococcus aureus lipase with human granulocyte function. Eur J Clin Microbiol Infect Dis 7:505–510 http://dx.doi.org/10.1007/BF01962601. [PubMed]
342. Rollof J, Vinge E, Nilsson-Ehle P, Braconier JH. 1992. Aggregation of human granulocytes by Staphylococcus aureus lipase. J Med Microbiol 36:52–55 http://dx.doi.org/10.1099/00222615-36-1-52. [PubMed]
343. Hu C, Xiong N, Zhang Y, Rayner S, Chen S. 2012. Functional characterization of lipase in the pathogenesis of Staphylococcus aureus. Biochem Biophys Res Commun 419:617–620 http://dx.doi.org/10.1016/j.bbrc.2012.02.057. [PubMed]
344. Shryock TR, Dye ES, Kapral FA. 1992. The accumulation of bactericidal lipids in staphylococcal abscesses. J Med Microbiol 36:332–336 http://dx.doi.org/10.1099/00222615-36-5-332. [PubMed]
345. Mortensen JE, Shryock TR, Kapral FA. 1992. Modification of bactericidal fatty acids by an enzyme of Staphylococcus aureus. J Med Microbiol 36:293–298 http://dx.doi.org/10.1099/00222615-36-4-293. [PubMed]
346. Chamberlain NR, Brueggemann SA. 1997. Characterisation and expression of fatty acid modifying enzyme produced by Staphylococcus epidermidis. J Med Microbiol 46:693–697 http://dx.doi.org/10.1099/00222615-46-8-693. [PubMed]
347. Long JP, Hart J, Albers W, Kapral FA. 1992. The production of fatty acid modifying enzyme (FAME) and lipase by various staphylococcal species. J Med Microbiol 37:232–234 http://dx.doi.org/10.1099/00222615-37-4-232. [PubMed]
348. Lu T, Park JY, Parnell K, Fox LK, McGuire MA. 2012. Characterization of fatty acid modifying enzyme activity in staphylococcal mastitis isolates and other bacteria. BMC Res Notes 5:323 http://dx.doi.org/10.1186/1756-0500-5-323. [PubMed]
349. Kapral FA, Smith S, Lal D. 1992. The esterification of fatty acids by Staphylococcus aureus fatty acid modifying enzyme (FAME) and its inhibition by glycerides. J Med Microbiol 37:235–237 http://dx.doi.org/10.1099/00222615-37-4-235. [PubMed]
350. Long JP, Kapral FA. 1993. Host response to coagulase-negative staphylococci in abscesses induced within mice. J Med Microbiol 39:191–195 http://dx.doi.org/10.1099/00222615-39-3-191. [PubMed]
351. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall’Acqua WF. 2014. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem 289:29874–29880 http://dx.doi.org/10.1074/jbc.M114.601328. [PubMed]
352. Roblin P, Guillet V, Joubert O, Keller D, Erard M, Maveyraud L, Prévost G, Mourey L. 2008. A covalent S-F heterodimer of leucotoxin reveals molecular plasticity of beta-barrel pore-forming toxins. Proteins 71:485–496 http://dx.doi.org/10.1002/prot.21900. [PubMed]
353. Olson R, Nariya H, Yokota K, Kamio Y, Gouaux E. 1999. Crystal structure of staphylococcal LukF delineates conformational changes accompanying formation of a transmembrane channel. Nat Struct Biol 6:134–140 http://dx.doi.org/10.1038/5821. [PubMed]
354. Okumura K, Shimomura Y, Murayama SY, Yagi J, Ubukata K, Kirikae T, Miyoshi-Akiyama T. 2012. Evolutionary paths of streptococcal and staphylococcal superantigens. BMC Genomics 13:404. [PubMed]
355. Benkerroum N. 2018. Staphylococcal enterotoxins and enterotoxin-like toxins with special reference to dairy products: An overview. Crit Rev Food Sci Nutr 58:1943–1970. [PubMed]
Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.GPP3-0039-2018
2019-03-15
2019-10-23

Abstract:

is a formidable pathogen capable of causing infections in different sites of the body in a variety of vertebrate animals, including humans and livestock. A major contribution to the success of as a pathogen is the plethora of virulence factors that manipulate the host’s innate and adaptive immune responses. Many of these immune modulating virulence factors are secreted toxins, cofactors for activating host zymogens, and exoenzymes. Secreted toxins such as pore-forming toxins and superantigens are highly inflammatory and can cause leukocyte cell death by cytolysis and clonal deletion, respectively. Coagulases and staphylokinases are cofactors that hijack the host’s coagulation system. Exoenzymes, including nucleases and proteases, cleave and inactivate various immune defense and surveillance molecules, such as complement factors, antimicrobial peptides, and surface receptors that are important for leukocyte chemotaxis. Additionally, some of these secreted toxins and exoenzymes can cause disruption of endothelial and epithelial barriers through cell lysis and cleavage of junction proteins. A unique feature when examining the repertoire of secreted virulence factors is the apparent functional redundancy exhibited by the majority of the toxins and exoenzymes. However, closer examination of each virulence factor revealed that each has unique properties that have important functional consequences. This chapter provides a brief overview of our current understanding of the major secreted virulence factors critical for pathogenesis.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Current models for PFT pore formation for (A) α-toxin and (B) the bicomponent PFTs. α-toxin is secreted as a monomer. Upon binding to the host receptor, ADAM-10, the toxin monomers oligomerize to form a heptameric prepore on the target cell surface. The prestem domains of the prepore then extend to form a β-barrel pore that punctures the target cell membrane. The bicomponent PFTs are also secreted as monomers (except LukAB, which is secreted as dimers). The S-subunit recognizes the target cell by binding to cell surface receptors (LukPQ is an exception; the F-subunit LukQ is the receptor recognition subunit). These receptors are typically G-protein-coupled receptors (except for LukAB, which binds to the integrin CD11b). Upon receptor binding, the S-subunit dimerizes with the F-subunit, followed by oligomerization of three additional leukocidin dimers, resulting in an octameric prepore. Similar to the α-toxin pore formation model, the prestem domains of the prepore extend to form a β-barrel pore, thus disrupting the target cell membrane.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Structures of (A to C) α-toxin and (D to G) the bicomponent PFT, HlgAB. The α-toxin monomer (PDB:4U6V) ( 351 ). The amino latch is colored blue, the cap domain red, the rim domain pink, and the prestem domain green. The α-toxin heptamer (7AHL) ( 4 ). Each α-toxin is colored a different shade of pink to denote individual protomers. The amino latches are highlighted in blue, and the β-barrel pore is green. The monomers of HlgA (2QK7) ( 352 ) and HlgB (1LKF) ( 353 ). The amino latch of HlgB is blue; the cap domain for HlgA is cyan and HlgB is beige; the rim domains are yellow for HlgA and pink for HlgB; and the prestem domains are green. The HlgAB octamer (3B07) ( 33 ). The HlgA protomers are cyan, the HlgB protomers are beige, and the β-barrel pore is green.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

PFTs and their receptor, species, and cell type specificities. Currently, is known to produce eight β-barrel PFTs. Each of these PFTs targets different cell surface receptors. While some PFTs share the same receptors, they can differ in their species specificity. Collectively, the PFTs exert their sublytic and lytic effects on a variety of cells, including erythrocytes, endothelial cells, epithelial cells, neutrophils, monocytes, macrophages, dendritic cells, and T cells.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Phylogenic tree of PFTs. The tree is constructed based on the mature protein sequences using the DNASTAR MegAlign ClustalW method for multiple sequence alignment.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5
FIGURE 5

Phylogenic tree of SAgs. The tree is constructed based on the mature protein sequences using the DNASTAR MegAlign ClustalW method for multiple sequence alignment.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 6
FIGURE 6

Crystal structures of superantigens in complex with their cellular targets. The T cell superantigen, SEB, in complex with the TCR and MHC II molecule (4C56) ( 116 ). SEB (blue) cross-links the α-chain of MHC (dark green) to the Vβ TCR (orange) to induce T cell proliferation that results in T cell anergy and/or apoptosis. The B cell superantigen, SpA (teal), in complex with the Fab fragment (pink/magenta) (1DEE) ( 138 ). Conventional antigens bind to B cell receptors at the complementarity-determining region (blue), a hypervariable region that confers antigen specificities. SpA binds at a constant region of the receptor to activate B cells for supraclonal expansion, which leads to clonal deletion of SpA-activated B cells.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 7
FIGURE 7

Overlay of the crystal structures of ETA and ETB. ETA (1EXF, green) ( 174 ) and ETB (1QTF, blue) ( 173 ) share high structural identity. ETs cause SSSS by cleaving Dsg1 at the epithelial cell junctions. Both ETs are serine proteases. Loop D and the catalytic triad are highlighted in pink for ETA and red for ETB.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 8
FIGURE 8

produces cofactors that hijack the host’s coagulation system. Coa and vWbp bind to prothrombin and alter the conformation of the protein to form the complex, staphylothrombin. This complex is highly active and cleaves fibrinogens to fibrins, promoting the formation of fibrinous clots. Sak binds to plasmin to form the Sak-plasmin complex. Sak stabilizes plasmin to enhance enzymatic activity. Sak-plasmin cleaves plasminogen to form plasmin, which breaks down fibrin clots.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 9
FIGURE 9

The crystal structure of Sak in complex with two plasminogen molecules (1BUI) ( 215 ). While Sak binding to plasminogen does not have enzymatic activity, the trimeric complex captures how Sak may bind to plasmin to cleave plasminogen. Sak (orange) is in complex with plasminogen (blue), exposing the catalytic site (red). Sak facilitates the docking of the substrate plasminogen (pink) to promote cleavage by plasmin.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 10
FIGURE 10

Staphylococcal protease cascade. The metalloprotease, Aur, is activated by autoproteolysis after protein secretion. Aur is required to activate the serine protease, SspA. SspA processes one of the staphopains, SspB, from zymogen to active enzyme. The other staphopain, ScpA, is activated by autoproteolysis. Both staphopains are inhibited by staphostatins prior to secretion. SspB is inhibited by SspC, and ScpA is inhibited by ScpB.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 11
FIGURE 11

Staphopain-staphostatin complex (1PXV) ( 293 ). Staphopain SspB (blue) has two domains: the L-domain is helical, and the R-domain consists of β-strands that fold into a β-barrel-like structure. The catalytic site of SspB is highlighted in red. Staphopain SspC (beige) is a single domain protein composed of eight β-strands forming a single mixed β-barrel domain. SspC is a competitive inhibitor of SspB, directly blocking substrate access to the active site.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 12
FIGURE 12

Phylogenic tree of Spls. The tree is constructed based on the mature protein sequences using the DNASTAR MegAlign ClustalW method for multiple sequence alignment. Crystal structure of SplA (2W7S) ( 299 ). SplA has two domains connected by a linker (cyan). Domain 1 (light purple) consists of α-helices and β-strands, and domain 2 (blue) consists of of β-strands. Both domains fold into a β-barrel structure. The catalytic triad (red) is located at the center between the two domains.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 13
FIGURE 13

secretes many different toxins and enzymes. Superantigens are proteins that have high mitogenic properties, causing T and B cell expansions that result in clonal deletion and massive cytokine production. Cytotoxins, such as α-toxin and the leukocidins, cause cytokine production, hemolysis, and leukocyte cell death through targeting specific cell surface receptors. The amphiphilic PSM peptides mediate cytolysis by inserting into the lipid bilayer of cell membranes. Enzymes, such as β-toxin and the ETs, cause cytotoxicity on mammalian cells, resulting in cell death, inflammation, and tissue barrier disruptions. Other enzymes, including various proteases and nucleases, mediate host protein degradations, thwarting many important host immune surveillance and defense molecules. These enzymes can also act on self-proteins to degrade biofilms for bacterial dissemination. Lipases and FAME work synergistically to degrade lipids in the environment for nutrients. Cofactors, including Coa, vWbp, and Sak, bind and activate host zymogens in the coagulation system to mediate clot formation and dissolution. Altogether, these toxins and enzymes provide critical nutrients (i.e., iron and carbon) that are important for the growth and survival of the bacteria. Importantly, they target various aspects of host immune defenses, thus contributing to the overall virulence of during infections.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Permissions and Reprints Request Permissions
Download as Powerpoint

Tables

Generic image for table
TABLE 1

Major exotoxins produced by

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Generic image for table
TABLE 2

Major secreted cofactors and enzymes produced by

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018
Generic image for table
TABLE 3

Consensus cleavage sequence of Spls

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0039-2018

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error